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SUMMARY 
Laryngeal cancer represents approximately 1% of the total of malignancies with an estimated 
incidence age-standardised rate of 4.4 per 100.000 persons. It is most commonly presented in 
males at their sixth decade of life. Anatomically, the larynx is an air passage and an organ of 
phonation that extends from the tongue to the trachea. Two different histologies are described in 
the larynx: the pseudostratified respiratory epithelium that covers the inner aspects of the larynx, 
and the non-keratinized, stratified squamous epithelium that covers the vocal folds and the 
exterior surfaces of the larynx. The vast majority of tumours arising the larynx are conventional 
squamous cell carcinomas (SCC), although there are other less frequent subtypes. SCC of the 
head and neck is considered now to be the final stage of a multi-step process in which loss of 
heterozygosity, amplifications, deletions, up and down-regulation oncogenes or tumour-
suppressor genes take part. The primary cause for head and neck cancer is tobacco use, where 
even a low quantity of cigarette smoking has been associated with an increased risk. Alcohol 
consumption is the second major risk factor, which potentiates the effects of tobacco. The most 
extended cancer staging system is the tumour node metastasis (TNM) system by the American 
Joint Committee on Cancer (AJCC). For non-metastatic patients, treatment options depend on 
whether the tumour is presented at early stages, or as locoregional disease. In general, early stages 
are treated with either surgery or definitive radiotherapy, while advanced stages require a 
multimodal approach. Three sparing approaches are accepted: radiotherapy, bio or chemotherapy 
with concomitant radiotherapy and induction chemotherapy followed by radiotherapy with or 
without bio/chemotherapy. Although functional organ sparing approaches allow larynx 
preservation, they do not provide a survival advantage over surgery. Moreover, those treatments 
confer significant toxicities and approximately 30-40% of patients will relapse or lead to an 
incompetent larynx. Predictive biomarkers would facilitate pre-treatment identification of 
patients who are unlikely going to be cured by radiation-based therapy. Managing these patients 
with surgery rather than with preservation approaches, local disease control and survival could be 
potentially optimized and unnecessary treatment related morbidities from unsuccessful larynx 
treatments avoided.  With this study we aim to find biomarkers that could be related with 
prognosis and being used as predictive biomarkers for pre-treatment patient selection. We 
evaluated 65 patients with larynx cancer treated at the Hospital Universitario Virgen del Rocío 
from August 2005 until February 2014. Eligibility criteria for treatment preservation include 
patients with stage II-IV laryngeal tumours that had no contraindication for chemotherapy and/or 
radiotherapy, significant cartilage destruction, or more than 2 cm tumoral invasion of the base of 
the tongue. Patients were mainly male with stage III supraglottic SCC and with a good general 
condition. Histological characterization of all samples was done by hematoxylin and eosin 
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staining, followed by immunohistochemistry analysis of tissue microarrays. Analysed markers 
included proliferation markers such as Ki67 or the activated form of ERK, apoptosis such as 
mutant p53 or activated AKT, and finally markers involved in the DNA-damage response (DDR) 
pathway such as MAP17, SGLT and pH2AX. Subsequent statistical analysis was performed, 
taking into consideration clinical and pathological factors. Concerning clinical factors, T4 
primary tumour extension and patients who needed a pre-treatment tracheotomy had worse 
laryngoesophageal dysfunction-free survival (LDS) and seemed not to benefit of preservation 
treatments. Moreover, receiving an optimal platinum dose determined LDS, as patients unable to 
complete treatment had worse prognosis. In what respects to pathological factors, markers related 
with the DDR were associated with survival. DDR is a network of cellular pathways that sense, 
signal and repair DNA lesions. MAP17 is a small membrane protein highly expressed in 
metastatic carcinoma. Its expression is associated with a SGLT-dependent reactive oxygen 
species (ROS) increase. While a mild increase in ROS activates signalling cascades that 
upregulate tumorigenic processes, further ROS increases lead to toxic cellular environment and 
to programmed cell death. Moreover, γH2AX is a component of the histone octamer in 
nucleosomes involved in recruiting DNA repair proteins in response to the presence of DNA 
double-strand breaks. Hence, it´s increasing is related to structural DNA damage. Therefore, 
DNA-damage produced by ROS would lead to pH2AX increasing. Laryngeal cancer tumours 
with high levels of ROS producing MAP17 and SGLT proteins and with high pH2AX expression 
should benefit from therapies such as cisplatin or radiotherapy that increase oxidative stress and 
could sensitize them to cell death. Our analysis confirmed a significant relationship between high 
MAP17 protein expression and increased overall survival (OS), locoregional control (LRC) and 
LDS. In fact, high MAP17 levels demonstrated better OS than low levels (67 months vs. 31.7 
months, IC 95%; p<0.001). In addition, high-MAP17 and high-SGLT showed improved OS, 
better than MAP17 alone. In our cohort, pH2AX was related to LDS (high-pH2AX HR 0.26, p = 
0.02). When analysed together pH2AX expression and dose of cisplatin received during radical 
treatment, there was a significant correlation with survival and LDS. Also, patients with high-
MAP17 and high-pH2AX showed to have better OS and LDS. Therefore, this work suggests that 
high levels of MAP17 induced ROS that in turn increases DNA-damage and DDR signalling, 
measured as high-pH2AX. Upon further DNA-damage and further increase in ROS molecules 
induced by cisplatin and RT treatment, tumours with higher oxidative stress, are more suitable to 
undergo apoptosis. The inherent DDR pathway activation biomarkers MAP17 and pH2AX are 
valuable prognostic markers in patients with laryngeal carcinoma who received organ 
preservation approaches. 
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RESUMEN  
El cáncer de laringe representa aproximadamente el 1% del total de las neoplasias, con una 
incidencia estimada estandarizada por edad de 4.4 cada 100.000 habitantes. Es más frecuente en 
varones durante la sexta década de vida. Anatómicamente, la laringe se extiende desde la lengua 
hasta la tráquea y conduce el aire siendo el órgano responsable de la fonación. Se compone 
fundamentalmente de dos tipos histológicos: epitelio respiratorio pseudoestratificado en la cara 
interna, y el epitelio no-queratinizado que envuelve las cuerdas vocales y la cara externa. La gran 
mayoría de los tumores laríngeos son carcinomas epidermoides, aunque existen otros subtipos 
menos frecuentes. Los cánceres de cabeza y cuello (CCyC) se consideran el estadio final de un 
complejo proceso que incluye pérdidas de heterocigosidad, amplificaciones, deleciones y 
alteraciones de la regulación de oncogenes y genes supresores de tumores. La causa más 
fundamental del CCyC es el tabaco, donde hasta un bajo consumo del mismo se ha asociado a un 
aumento del riesgo de cáncer.  El segundo factor es el alcohol, que potencia el efecto del tabaco. 
El sistema de clasificación más frecuentemente utilizado es el TNM por sus siglas en inglés 
“tumour, node, metastasis” elaborado por la American Joint Committee on Cancer (AJCC). El 
tratamiento de los pacientes no metastásicos depende de si la enfermedad se ha presentado en un 
estadio inicial o como enfermedad locoregional. En general, los estadios iniciales se benefician 
de cirugía o radioterapia, mientras que los avanzados requieren de un abordaje multidisciplinar. 
Tres estrategias terapéuticas están aceptadas: radioterapia, bio o quimioterapia concomitante con 
radioterapia y quimioterapia de inducción seguida por radioterapia con o sin bio/quimioterapia. 
Aunque las terapias de preservación de órgano permiten conservar la laringe, no han demostrado 
aumentar la supervivencia en comparación con cirugía. Además, estos tratamientos conllevan 
importantes toxicidades y en un 30-40% los pacientes sufren recidivas o pierden la funcionalidad 
de la laringe. Disponer de biomarcadores predictivos facilitaría la identificación de aquellos 
pacientes que no se van a beneficiar de tratamiento basado en la radioterapia. Derivando estos 
pacientes directamente a cirugía, el control local de la enfermedad y potencialmente la 
supervivencia podrían optimizarse y evitar toxicidades innecesarias. Con este estudio se pretende 
identificar biomarcadores pronósticos que puedan llegar a ser predictivos para la selección de 
pacientes. Se han evaluaron 65 pacientes con cáncer de laringe tratados en el Hospital 
Universitario Virgen de Rocío entre agosto de 2005 y febrero de 2014. Los criterios de selección 
para la preservación de órgano incluyeron estadios II a IV de cáncer de laringe, sin 
contraindicación para quimio o radioterapia, ni destrucción significativa de cartílago o invasión 
mayor de 2 cm de la base de la lengua. Los pacientes fueron mayoritariamente varones con 
carcinomas epidermoides estadio III y buen estado general. Se procedió a la caracterización 
histológica de todas las muestras mediante tinción de hematoxilina-eosina seguido de 
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inmunohistoquímica de los microarrays. Se han estudiado marcadores de proliferación como 
Ki67 y la forma activada de ERK, de apoptosis como la mutación de p53 o la forma activada de 
AKT y finalmente marcadores implicados en los mecanismos de reparación del daño de ADN 
(RDA) como MAP17, SGLT y pH2AX. Posteriormente se llevó a cabo el estudio estadístico 
tomando en consideración tanto los factores clínicos como histopatológicos. Respecto a los 
factores clínicos, la extensión del tumor primario T4 y aquellos pacientes que precisaron de 
traqueotomía previa al tratamiento obtuvieron una peor supervivencia con laringe funcionante 
(SLF) y parecen no beneficiarse de tratamientos de preservación de órgano. Por otro lado, recibir 
una dosis óptima de platino durante el tratamiento influyó en la SLF ya que aquellos que no lo 
completaron tuvieron un peor pronóstico. Respecto a los factores moleculares, las marcadores 
relacionados con la RDA se asociaron a supervivencia. Los mecanismos RDA conforman una red 
de diagnóstico, señalización y reparación de las lesiones producidas en el ADN. MAP17 es una 
proteína de membrana altamente expresada en carcinomas. Dicha expresión se asocia a un 
aumento de las especies de oxígeno reactivo (EOR) dependiente de SGLT. Mientras que 
incrementos moderados de EOR activan cascadas de señalización que activan los procesos 
tumorigénicos, un aumento más significativo conlleva a un ambiente celular tóxico dando lugar 
a la muerte celular programada. Por otro lado, γH2AX es un componente del octámero de la 
histona del nucleosoma encargado de reclutar proteínas de reparación de ADN en respuesta al 
daño de la doble cadena de ADN. Por tanto, su aumento se relaciona con daño de ADN. Ya que 
ROS produce daño de ADN, pH2AX debería aumentar en este contexto. La hipótesis es que 
aquellos tumores laríngeos con niveles altos de ROS producidos por MAP17 y SGLT, y con 
expresión de pH2AX podrían beneficiarse de terapias como el cisplatino y la radioterapia, que 
aumentan el estrés oxidativo y dar lugar a la muerte celular. El análisis confirmó que existe una 
relación entre MAP17 y el aumento de la supervivencia global (SG), control locoregional (CLR) 
y SLF. Niveles altos de MAP17 se asociaron a un aumento de SG estadísticamente significativo 
comparado con niveles bajos (67 meses vs. 31.7 meses, IC 95%; p<0.001). La combinación de 
niveles altos tanto de MAP17 como de SGLT obtuvieron mejor SG que MAP17 solo.  Por otro 
lado, pH2AX se correlacionó con SLF (alto-pH2AX HR 0.26, p = 0.02). El análisis conjunto de 
pH2AX junto con una dosis óptima de platino también se correlacionó con SG y SLF, 
demostrando resultados similares el análisis de pH2AX junto con alto-MAP17. Por tanto, niveles 
altos de MAP17 inducen EOR dando lugar a un aumento del daño de ADN y de los procesos de 
RDA, medido indirectamente por el aumento de pH2AX. En este tipo de tumores con alto estrés 
oxidativo, el sucesivo daño producido por terapias basadas en platino y la radiación tienen una 
mayor sensibilidad a la apoptosis. Por tanto, los biomarcadores implicados en los mecanismos de 
RDA MAP17 y pH2AX son marcadores pronósticos para aquellos pacientes con cáncer de laringe 
candidatos a terapias de preservación de órgano. 
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1.1 LARYNX CANCER EPIDEMIOLOGY 
Around 157.000 new cases of laryngeal cancer were diagnosed worldwide in 2012, which 
represents approximately 1% of the total of malignancies. The estimated general incidence age-
standardised rate (ASR) is 4.4 per 100.000 persons, with a broad difference between males and 
females (8.8 versus –vs- 0.8). In Europe, laryngeal cancer is the 20th most common tumour, with 
39.900 new cases diagnosed in 2012; in contrast, the United States (US) registered 12.300 new 
cases in the same period. Worldwide, the highest incidence rate is found in the Caribbean area 
and are lowest in Western Africa, but this may just reflect varying data quality worldwide though 
(1).  
On the other hand, estimated general mortality ASR is 2.1 per 100.000 persons; 4.3 males and 0.3 
women. Worldwide, the highest ASR mortality rates for laryngeal cancer are in Hungary for men 
and Albania for women (1). In contrast, the lowest rates are found in Iceland for both men and 
women. Mortality differs significantly between European countries. Males have lowest mortality 
rates in Northern Europe (ASR 1.9) followed by Southern Europe (ASR 4.3) and finally Eastern 
Europe (ASR 7.0) (Figure 1).  Spain has similar mortality rates to the rest of Southern Europe 
countries, with a male ASR of 4.3 and female ASR of 0.3; however, those numbers are still far 
away from Northern countries (2) (Table 1). 
 
Larynx cancer 
in Spain 
Incidence Mortality 5-year prevalence 
Total (%) ASR Total (%) ASR Total (%) ASR 
All population 3.182 1,5 4,1 1.321 1,3 1,5 11.200 1,9 28,3 
Male 2.914 2,3 7,8 1.235 1,9 2,9 10.246 3,1 52,7 
Female 268 0,3 0,7 86 0,2 0,2 954 0,4 4,7 
ASR: age-standarized rate.  
Table 1. Estimated Incidence, Mortality and 5-year prevalence in Spain, 2012. Source: Spanish Society of 
Medical Oncology annual report (6).  
The incidence of laryngeal cancer is falling in developed countries, because of the success of risk 
factors prevention campaigns. However, population growth and increased aging still results still 
in a larger number of total annual cases. During the last twenty years, larynx cancer has decreased 
globally by a 25% (3); for example, in the US the rate of decreasing is about 2% to 3% per year (4) 
(Figure 2). In Spain, the incidence in 2012 was 3182 cases, and the prediction of the World Health 
Organization (WHO) for 2020 is of 3735 new cases. However, this slight increase in total 
numbers translates a decreasing rate of 19.4% since 2003-07 (5). Therefore, the incidence of 
laryngeal carcinoma shows a decreasing trend for for both sexes in our country similar to the rest 
		 	
20	
of Europe and the US. But also within Spain, there is a significant variability. In the period 2003-
2007, male incidence varied from 8.9 per 100.000 habitants in Albacete to 13.1 in the Basque 
Country. For females, Cuenca was found to be the region with a lower incidence and the Basque 
Country the highest rate (0.1 vs 0.8/100.000). Therefore, the Basque Country is the autonomous 
community with a higher incidence of laryngeal cancer. This variability is influenced by the 
differences in the prevalence of alcohol and tobacco consumption between regions (5).  
 
 
 
Figure 1. Worldwide laryngeal cancer incidence and mortality. Source: International Agency for 
research on cancer - World Health Organization. GLOBOCAN 2012. 
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However, the Surveillance, Epidemiology, and End Results (SEER) program of the National 
Cancer Institute in the US, has established that 5-year relative survival has slightly dropped during 
the last decades. In numbers, the 5-year survival decreased by a 3.3% from 1985 until 2008. 
Although this fact has coincided in time with the implantation of preservation approaches, they 
were not broadly used and standardized by then and major conclusions may not be extrapolated 
(4). Interestingly, in a recent publication it was found that in the US, uninsured patients or Medicaid 
patients (joint federal-state program that provides health coverage) had a decreased relative 
survival when compared to privately insured individuals (7), being one of the facts that could 
modify general survival. On the other hand, in the United Kingdom (UK) statistics show a trend 
towards improved survival over the last decades. A 5.5% increasing of the 5-year relative survival 
has been observed from 1990 till 2011 (69.8% survival in the period 2010-2011) (8). In Spain, 5-
year relative survival was around 60% survival in the period of 2000-2007, so in the range of 
developed countries (6).  
 
Figure 2. Number of new cases, deaths and 5-year relative survival in US. Source: SEER Cancer 
Statistics. 
Median age at presentation is 65 years, where it is most frequently diagnosed among people aged 
55-64, in a 30.9% of the cases (4). This is similar for both developed and emerging countries, as 
some series in India showed maximum incidence between the 60-69 years (31.93%) (9). In the US, 
at the time of diagnosis most patients have locoregional disease (77%); of them, 55% localized 
disease and 22% regional disease. As metastatic disease is found as a later event in laryngeal 
cancer, only 19% were found to have them (4). In conclusion, laryngeal cancer is more prevalent 
in males than females, aged around the sixth decade of life, and frequently diagnosed as localized 
or locoregional disease. There are significant incidence variations worldwide that depends mainly 
on risk factors habits. In Europe, laryngeal cancer rates are dropping but there are still differences 
between North, Central and South regions. Finally, Spain behaves similar to other Mediterranean 
countries, but there are areas where the incidence is still high.  
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1.2 ANATOMY AND HISTOLOGY OF THE LARYNX. PATTERNS OF SPREAD. TNM 
STAGING  
	
1.2.1. General Anatomy, histology and pathology 
General Anatomy 
The larynx is an air passage and an organ of phonation that extends from the tongue to the trachea. 
It projects ventrally between the great vessels of the neck and is covered anteriorly by skin, fasciae 
and the infrahyoid strap muscles that lower the hyoid bone and the larynx. Above, it opens into 
the laryngopharynx and forms its anterior wall; below, it continues into the trachea. Until puberty, 
male and female larynges are similar in size. After puberty, the male larynx enlarges considerably 
in comparison with the female. 
Skeletal framework. The skeletal framework of the larynx is formed by cartilages interconnected 
by ligaments and fibrous membranes. The laryngeal cartilages are the single thyroid, cricoid and 
epiglottic cartilages, and the paired arytenoid, cuneiform and corniculate cartilages (Figure 3). 
The hyoid bone is not part of the larynx but provides the muscular attachments from above that 
aid in laryngeal motion. Larynx cartilages are joined to surrounding structures by extrinsic 
membranes. It is also interconnected by intrinsic ligaments and fibrobroelastic membranes, of 
which the thyrohyoid and quadrangular membranes, together with the conus elasticus, are the 
most significant. The thyrohyoid membrane is external to the larynx, whereas the paired 
quadrangular membranes and conus elasticus are internal. The named ligaments are the anterior 
cricothyroid ligament, the hyoepiglottic and thyroepiglottic ligaments, and the cricotracheal 
ligament.  
 
 
Figure 3.  General laryngeal anatomy. Version adapted from the Human Anatomy Atlas, Netter 2nd Edition. 
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Laryngeal cavity. The walls of the cavity are formed of fibroelastic membranes and lined with 
mucous membrane that folds over the free edges of these membranes within the larynx. On either 
side, the continuity of the fibroelastic membrane is interrupted between the upper vestibular and 
lower true vocal folds. The folds project into the lumen of the cavity and divide it into upper and 
lower parts, separated by a middle portion between the two sets of folds that leads into the 
laryngeal ventricle. The upper folds are the vestibular (ventricular or false vocal) folds; the 
median aperture between them is the rima vestibuli. The lower pair is the (true) vocal folds, 
primary source of phonation.  
In tumor staging the supraglottis refers to all those parts of the larynx that lie above the glottis, 
meanwhile the glottis is defined as the anterior and inferior surfaces of the true vocal folds and 
the anterior and posterior commissures. Finally, the subglottis is the region below the glottis that 
extends to the inferior border of the cricoid cartilage.  
Muscles. The muscles of the larynx may be divided into extrinsic and intrinsic groups. The 
extrinsic muscles connect the larynx to neighbouring structures and are responsible for moving it 
vertically during phonation and swallowing, thus opposite to the infrahyoid muscles that lower 
the larynx. They include the infrahyoid strap muscles, thyrohyoid, sternothyroid and sternohyoid, 
and the inferior constrictor muscle of the pharynx. The extrinsic muscles can affect the pitch and 
the quality of the voice by raising or lowering the larynx, and geniohyoid elevates and anteriorly 
displaces the larynx, particularly during deglutition.  
The intrinsic laryngeal muscles may be placed in three groups according to their main actions. 
The posterior and lateral cricoarytenoids and oblique and transverse arytenoids vary the degree 
of abduction and adduction of the vocal folds and thus the dimensions and the degree of opening 
of the rima glottidis. The cricothyroids, posterior cricoarytenoids, thyroarytenoids and vocalis 
regulate the length and tension of the vocal folds. The third group of muscles is the oblique 
arytenoids, aryepiglottic and thyroepiglottic muscles, which modify the laryngeal inlet.  
Vascular supply and inervation. The blood supply of the larynx is derived mainly from the 
superior and inferior laryngeal arteries. Rich anastomoses exist between the corresponding 
contralateral laryngeal arteries and between the ipsilateral laryngeal arteries. The superior 
laryngeal arteries supply the greater part of the tissues of the larynx, from the epiglottis down to 
the level of the vocal cords, including the majority of the laryngeal musculature. The inferior 
laryngeal artery supplies the region around cricothyroid, while its posterior laryngeal branch 
supplies the tissue around posterior cricoarytenoid. The larynx is innervated by the internal and 
external branches of the superior laryngeal nerve, the recurrent laryngeal nerve and sympathetic 
nerves. Conventionally, the internal laryngeal nerve is described as sensory, the external laryngeal 
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nerve as motor, and the recurrent laryngeal nerve as mixed.  
Lymphatic drainage. The upper deep cervical lymph nodes act as pathways for the spread of 
malignant tumours of the supraglottic larynx. Up to 40% of these tumours will have undergone 
such spread at the time of clinical presentation, mainly along the superior laryngeal artery draining 
to the deep cervical lymph nodes at the bifurcation of the common carotid artery. On the contrary, 
the glottis is very poorly endowed with lymphatic vessels; some 95% of malignant tumours 
confined to the glottis will present with no spread to adjacent lymph nodes. Tumours of the 
subglottic larynx will often spread to the paratracheal lymph node chain prior to clinical 
presentation. The paratracheal lymph nodes occupy a deep-seated position in the root of the neck 
(Figure 4) and so their enlargement may remain occult (10-16).  
 
    Figure 4. Cervical lymph node chains.  
 
Laryngeal histology 
The laryngeal mucosa is continuous with that of the pharynx above and the trachea below. Over 
the vocal folds, it is thinner and is firmly attached to the underlying vocal ligaments. The laryngeal 
epithelium is mainly a ciliated, pseudostratified respiratory epithelium that covers the inner 
aspects of the larynx, and it provides a mucociliary clearance mechanism shared with most of the 
respiratory tract. The vocal folds, however, are covered by non-keratinized, stratified squamous 
epithelium; this important variation protects the tissue from the effects of the considerable 
mechanical stresses that act on the surfaces of the vocal folds. The exterior surfaces of the larynx, 
which merge with the laryngopharynx and oropharynx, are subject to the abrasive effects of 
swallowed food, and are therefore also covered by non-keratinized, stratified squamous 
epithelium (Figure 5). The laryngeal mucosa has numerous mucous glands, especially over the 
epiglottis, and along the margins of the aryepiglottic folds anterior to the arytenoid cartilages. (11, 
17).  
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             Figure 5. Laryngeal cavity histology subtypes.  
 
Laryngeal pathology 
The vast majority of all laryngeal malignancies (95%) are conventional squamous cell carcinomas 
(SCC). They vary according to their degree of differentiation to well, moderate and poor 
carcinomas. Glottic cancers are generally well differentiated and have a less aggressive behaviour 
in comparison with carcinomas at the other sites of the larynx. SCC often arises in a background 
of mucosal squamous dysplasia or carcinoma in situ and typically presents islands, tongues and 
clusters of atypical cells invading the laryngeal stroma. Features of squamous differentiation also 
comprise individual cell keratinisation, intercellular bridges and keratin pearls (17).  
Recognition of the less common variants is significant because their biological behaviour is often 
different from conventional SCC.  
Verrucous SCC: comprises approximately 1% to 4% of laryngeal malignancies. It presents as a 
locally invasive fungating mass that can be confused with a benign process and characteristically 
does not metastasize to regional lymph nodes. Histologically, it appears broad pegs of highly 
differentiated squamous cells invading the laryngeal stroma in a pushing pattern, and mitoses 
rarely found. Surgical excision is the cornerstone of therapy since radiotherapy is associated to 
poor results and with the possibility of anaplastic transformation of the tumour (18).  
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Spindle cell carcinomas (SpCC) are a rare variant of the squamous cell carcinoma (SCC). It is 
more predominant in males with a male-to-female ratio of nearly 7:1. Smoking, alcohol 
consumption, and previous irradiation are predisposing factors. It presents usually as a polypoid 
or less as an endophytic mass. SpCC consist of elongated (spindle) cells of epithelial origin, 
representing an unusual form of poorly differentiated SCC though morphologically these 
resemble a sarcoma. The most common site of origin in the head and neck region is the glottis 
and hypopharynx. In comparison with SCC, laryngeal SpCC appear to be more likely to present 
at an earlier stage. The metastatic potential of both entities seems to be similar. Surgery is 
considered to be the mainstay in the management of SpCC, as the effectiveness of radiotherapy 
was not confirmed in recent studies and the role of chemotherapy remains unclear (19).  
Basaloid SCC: usually presented at an advanced stage with neck metastases. Microscopically, the 
tumour is characterized by nests and lobules of small basaloid cells with a high nuclear-to-
cytoplasmic ratio and areas demonstrating abrupt squamous differentiation, foci of carcinoma in 
situ or invasive SCC. Comedonecrosis and stromal hyalinosis are also common findings. Surgery 
of the primary tumour and neck and radiation therapy is the usual therapeutic approach (20).  
Other tumors such as minor salivary gland tumors are rare; even rarer are soft tissue sarcomas, 
lymphomas, small cell neuroendocrine carcinoma, and plamacytomas. Hemangiomas, 
chondromas, and osteochondromas are reported, but their malignant counterparts are rare (21).  
 
1.2.2. Patterns of spread 
According to the location of the primary tumour there are different patterns of spread:  
Supraglottis 
Suprahyoid Epiglottis. Lesions may grow producing exophytic mass with little tendency to 
destroy cartilage or spread to adjacent structures. Others may infiltrate and destroy cartilage. The 
tend to invade the vallecula, pre-epiglottic space, lateral pharyngeal walls, and the rest of the 
supraglottis.  
Infrahyoid Epiglottis. Lesions tend to produce irregular tumour nodules with invasion through the 
porous epiglottic cartilage into the preepiglottic space. They grow circumferentially to involve 
the false cords, aryepiglottis folds, and eventually, the medial wall of the pyriform sinus and the 
pharyngoepiglottic fold (21, 22).   
Lymphatic drainage is initially to the level II nodes and then to levels III and IV. The incidence 
of clinically positive nodes is 55% at diagnosis, 16% are bilateral (23).   
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Glottis 
Early false cord carcinomas usually have the appearance of a submucosal mass and are difficult 
to delineate accurately. They extend toward the thyroid cartilage and medial wall of the pyriform 
sinus. Extension to the infrahyoid epiglottis is common. Initial invasion of the vocal cord may 
occur submucosally and may be difficult to detect. Vocal cord invasion is often associated with 
thyroid cartilage invasion.  
On the other hand, the majority of lesions of the vocal cord begin on the free margin and upper 
surface and are easily visible. When diagnosed, about two-thirds are confined to one cord, usually 
the anterior two thirds of the cord. Extension to the anterior commissure is frequent. As the lesion 
enlarges, it extends to the ventricle, false cord, vocal process of the arytenoids, and subglottis. 
Infiltrative lesions invade the vocal ligament and thyroarytenoid muscles, eventually reaching the 
thyroid cartilage. The conus elasticus initially acts as a barrier to subglottic extension. Advanced 
glottis lesions eventually invade through the thyroid cartilage or thyrocricoid membrane to enter 
the neck and/or thyroid gland (21, 22).  
The incidence of clinically positive nodes at diagnosis varies with tumour stage: T1, 1% or less, 
T2, 5% or less; and T3 or T4, 20-30% (24). Supraglottic spread is associated with metastasis to the 
level II nodes. Anterior commissure and subglottic invasion is associated with levels III and IV 
and Delphian node involvement (25). 
Aryepiglottic fold and arytenoid 
Early lesions are usually exophytic. As the lesions advance, they extend to adjacent sites and 
eventually cause laryngeal fixation due to invasion the the cricoarytenoid muscle and joint. 
Advanced lesions invade the base of the tongue, pharyngeal wall, and postcricoid pharynx.  
Subglottic larynx 
They are in general uncommon. It is difficult to determine whether a tumour started on the under 
surface of the vocal cord or in the subglottis with extension to the cord. They involve the cricoid 
cartilage early, because there is no intervening muscle layer. Cord fixation is common (21). A 10% 
incidence of clinically positive lymph nodes has been reported. Spread is primarily to the 
Delphian nodes and the level IV nodes (26).  
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1.2.3. AJCC staging and survival 
The extend of cancer at the time of diagnosis is a key factor that defines prognosis and is a critical 
element in determining appropriate treatments based on the experience and outcomes of groups 
of prior patients with similar stage. 
 Several cancer staging systems are used worldwide. The most clinically useful staging system is 
the tumour node metastasis (TNM) system maintained collaboratively by the American Joint 
Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC). The TNM 
system classifies cancers by the size and extent of the primary tumour (T), involvement of 
regional lymph node (N), and the presence or absence of distant metastases (M). The last edition 
of the TNM classification is the 7th published in 2010 which has been the one used for this work. 
 
 
 
 
 
 
 
 
 
 
 
               Table 2. Anatomical laryngeal subsites. Source: AJCC, TNM classification, 7th edition. 
Site Subsite 
Supraglottis Suprahyoid epiglottis 
Infrahyoid epiglottis 
Aryepiglottic folds, arytenoids 
Ventricular bands (false cords) 
Glottis True vocal cords, including anterior and posterior 
commissures 
Subglottis Subglottis  
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Figure 6.  Five-year relative survivals by combined AJCC stage, 1998-1999. A:  SCC of the larynx. B. 
carcinoma of the glottis. C. carcinoma of the supraglottis. D. Carcinoma of the subglottis. Source: AJCC, 
TNM classification, 7th edition. 
 
 
Although the regional lymph node and metastasis classification is common for the different sites 
of the larynx, the primary tumour is divided into three parts: supraglottis, glottis and subglottis. 
Also within these three parts there are different subsites as it can be seen in Table 2 (27).  
Survival depends on the location of the primary tumour, where the glottis has a better survival 
(90% survival for stage I), followed by subglottis (65% survival for stage I). This difference is 
maintained for all T stages (27,28) (Table 3). 
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1.3 RISK AND PROGNOSTIC FACTORS FOR LARYNGEAL CANCER 
 
1.3.1. Risk factors of laryngeal cancer 
The primary cause for head and neck cancer (HNC) is tobacco use (29). There is a 7-fold increased 
risk of developing laryngeal cancer for smoker patients and, even though the risk drops for former 
smokers, it is still more than 4-folf compared to never smokers (30). Also, a low quantity of 
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cigarette smoking is associated with an increased risk of head and neck cancer. The results from 
the INHANCE consortium pooled analysis showed that smoking 3-5 cigarettes per day was 
particularly predictor of laryngeal cancer with an odds ratio (OR) of 3.48. However, the risk for 
low smoking frequency was not found among smokers with smoking duration shorter than 20 
years, suggesting that low frequency of cigarette consumption contributes to HNC, but that 
smoking duration seems to play at least an equal or stronger role (31).  
 
 
 
 
 
 
 
 
 
Figure 7. European Commission campaign for tobacco prevention approved in 2005. 
Source: http://www.who.int/tobacco/healthwarningsdatabase/ 
 
In the same way, it has been observed that young patients had a higher proportion of oral tongue 
cancer and oral cavity/oropharynx cancer with a lower proportion of larynx cancer than older 
adult cases, most probably because of the reduced length of exposure to tobacco (32). Cigar or pipe 
smoking elevate also HNC risk (OR 3.49 and 3.71, respectively) (33). In addition, survival 
duration, risk of recurrence, vulnerability to a second primary neoplasm, and treatment efficacy 
are also affected by continued smoking after HNC diagnosis and treatment. Survival is influenced 
by whether the patient ceases to smoke once diagnosed or continues to smoke during of following 
treatment (34-35). There has been found a relationship between continued smoking and survival 
among 115 patients with stage III or IV squamous cell carcinoma of the head and neck. Thirty-
nine percent of patients who smoked lived at least 2 years after diagnosis, compared with 66% of 
non-smokers (35). Decreased survival in patients that continue smoking is associated to the risk of 
recurrence but also to second primary tumours development. In a study, patients who continued 
to smoke were twice as likely to experience a disease recurrence compared with patients who 
abstained following treatment (36). Current smokers are four times as likely to develop a second 
primary tumour compared to former smokers, and this risk increased with the duration and 
		 	
32	
intensity of smoking. Particularly in laryngeal cancer, it has been seen that risk of a second 
primary tumour was proportional to the level of exposure (37, 38). Data also suggest that smoking 
may have an adverse effect on the response to medical treatment. In a prospective trial with more 
than one hundred patients it was seen that patients that stopped smoking during trial had better 
results than those who did not (75% of complete tumour responses vs 45%) (35). Also in terms of 
toxicities and comorbidities, patients that continue smoking have more treatment-related 
complications. Mucositis for example takes a longer time to heal in smoker patients than in non-
smokers during radiotherapy treatment (39). Moreover, population with HNC has also an increased 
risk of deep venous thrombosis, pulmonary embolism, and impaired wound healing following 
surgery which compromise treatments and outcomes (40, 41). Taking into account the risk of cancer 
development, cardiovascular disease and other related diseases to tobacco, it is estimated that 
smoking kills nearly 6 million people each year worldwide, more than HIV/AIDS, tuberculosis 
and malaria combined. Tobacco consumption imposes a considerable cost upon society, including 
direct healthcare costs and indirect costs due to absenteeism and premature death. In the European 
Union for the year 2000, cost was estimated to be approximately €363 billion (42).  
Alcohol is the second major risk factor for laryngeal cancer, which potentiates the effects of 
tobacco. The association between alcohol drinking and laryngeal cancer was first reported in a 
case-control study in the 1950s (43). In 1987, the International Agency for Research on Cancer 
working group classified alcoholic beverages as ‘‘carcinogenic to humans” and concluded that 
laryngeal cancers are causally related to the consumption of alcoholic beverages (44), a conclusion 
that was reaffirmed in a more recent evaluation in 2009 (45). The risk is proportional to the amount 
of ethanol drunk per day, as a meta-analysis reported in 2001. Laryngeal cancer relative risk (RR) 
adjusted by smoking status was 1.29 (1.23–1.36), 1.68 (1.53–1.84), and 2.72 (2.36–3.30) for 
drinking 25, 50, and 100 g of ethanol per day, respectively (46). However, in another meta-analysis, 
significant association was not found for light alcohol drinking (≤1 drink/day), RR = 0.88; 95% 
CI: 0.71–1.08), whereas moderate drinking (>1 to <4 drinks/day) was associated with a 1.5-fold 
increase in risk (RR = 1.47; 95% CI: 1.25–1.72) and heavy drinking (≥4 drinks/day) with a 2.5-
fold increased risk (RR = 2.62; 95% CI: 2.13–3.23). Overall, alcohol drinking versus non-
drinking was associated with an approximately 2-fold increase in risk of laryngeal cancer. In this 
meta-analysis, subgroup analyses for studies that adjusted for main potential confounding factors 
(age, sex, and tobacco use) and several further subgroup analyses showed similar results, which 
suggest the robustness of the results (47).  
Human papillomavirus (HPV) is emerging as an important HNC factor in developed countries, 
especially in oropharyngeal tumours. HPV-induced HNC has distinct epidemiology and biology, 
and a more favourable prognosis compared to HPV negative tumours. In patients with 
oropharyngeal carcinoma treated with chemoradiotherapy, HPV-positive had better 3-year 
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overall survival rates than patients with HPV-negative tumours (82.4%, vs. 57.1%; P<0.001) (48). 
In another trial with more than five thousand patients with HNC it was observed that the hazard 
ratio for death in patients HPV positive was 0.42 and that they had a better response to therapy. 
Positivity for HVP was found in 22% of patients, most of them having the HPV 16 positive 
genotype (49,50). However, it is known that there is a low rate of HPV-positive tumours among the 
laryngeal cancer population, which is estimated in around 1.6-6.5%.  Therefore, although HPV is 
emerging as an important risk factor that correlates with prognoses in HNC, the role in laryngeal 
cancer it is probably less relevant and it is not yet stablished (51-53).  
A recent meta-analysis supports the association of exposure to asbestos with an increased risk of 
laryngeal cancer mortality among male workers, with a standardized mortality rate of 1.69 (54).  It 
has been also suggested that there is an additive joint effect between asbestos exposure and 
alcohol consumption, and a more than additive joint effect between asbestos exposure and tobacco 
consumption, as well as between the three of them together (55). In a multicentre case-control study 
conducted in four European countries it was evaluated the role of occupational exposures and risk 
of laryngeal and hypopharyngeal cancer. Elevated risks for ever exposure to coal dust were found 
for both hypopharyngeal (OR= 4.19, 95% CI: 1.18, 14.89) and laryngeal cancer (OR= 1.81, 95% 
CI: 0.94, 3.47), with clear dose-response patterns. Laryngeal cancer was significantly associated 
with exposure to hard-alloys dust (OR = 2.23, 95% CI: 1.08, 4.57) and chlorinated solvents (OR 
= 2.18, 95% CI: 1.03, 4.61), without dose-response relations. A possible link between high 
formaldehyde exposure and laryngeal cancer was also suggested but further studies are required 
(56). Gastroesophageal reflux is another risk factor for laryngeal cancer as it was shown is a 
systematic review where the pooled odds ratio (OR) was 2.21 (95%, CI= 1.53-3.19), regardless 
of age, gender, tobacco and alcohol consumption (57). 
Genetic susceptibility has been implicated in HNC. Emerging phenotypic and genotypic data 
support the idea of genetic susceptibility for HNC. In an historical cohort study the RR for HNC 
was 7.89 (CI-1.50 to 41.6) in first degree relatives of patients with multiple primary head and 
neck cancer (58). In a more recent pooled analysis with 8.967 HNC cases and 13.627 controls, 
having a family history of HNC in first-degree relative increased the risk of HNC 1.7, which was 
higher when the affected relative was a sibling (OR= 2.2, 95% CI 1.6-3.1) rather than a parent 
(OR=1.5, CI 1.1-1.8) and for more distal HNC anatomic sites (hypopharynx and larynx) (59). 
Instead, vegetable, fruits, and vitamin C intake might reduce the risk of laryngeal cancer. Higher 
intakes of vitamin C were inversely related to laryngeal cancers (OR = 0.52, 95% CI: 0.40-0.68) 
in a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium (60). In 
another study, total vegetable and fruit consumption was inversely associated with risk of HNC 
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(OR=0.61, CI 0.44-0.85) and all HNC subtypes, with the strongest associations for oropharyngeal 
cancer (61). 
 
1.3.2. Clinical and pathological prognostic factors 
For laryngeal cancer, the main prognostic factor for overall survival (OS) is tumour staging. 
Pathologic tumour volume was found to be an independent predictive factor for distant metastasis, 
overall survival, disease-free survival and locoregional recurrence (62). T4 primary extension and 
more than 2 cm tumoral invasion of the base of the tongue increased salvage laryngectomy in the 
Veterans study (63). Moreover, lymph node invasion and extracapsular extension are also 
independent predictive factors for survival (62). Location of the primary tumour also plays a 
significant role in prognosis, as supra and subglottic cancers have worse prognosis than glottis 
cancers, probably in relation to earlier detection, and later node extension (27,28). Other prognostic 
factors are patient’s comorbidity and performance status-ECOG (PS) (64), most probably because 
frail patients are not suitable candidates for aggressive treatment management. Finally, surgical 
resection margins affection and pretreatment need for a tracheotomy have been related to poor 
disease-free survival (65,66).  However, none of those factors have been validated for treatment 
decision-making so far.  
 
1.4 MOLECULAR BIOLOGY OF LARYNGEAL CANCER 
 
1.4.1. Genetic susceptibility 
Genetic polymorphisms variants in tobacco carcinogen and alcohol metabolism genes may 
increase HNC risk. GSTM1 null genotype appears to confer increased HNC and particularly 
laryngeal increased risk (OR=1.22, 95% CI 1.1-1.36) (67, 68). The variant Val allele of the CYP1A1 
Ile462Val polymorphism is another consistent susceptibility maker for HNC, with a 35% 
increased risk in a meta-analysis of 12 studies (68). Presenting fast metabolizing alleles for alcohol 
dehydrogenase (ADH), ADH1B and ALDH2 genes, resulted in increased acetyladehyde levels 
and associated with HNC significantly interacting with alcohol consumption (69). In a case-control 
study single nucleotide polymorphisms (SNPs) in nucleotide excision repair (NER) genes such 
as ERCC5, ERCC6 and RAD23B could modify laryngeal cancer risk. In particular, ERCC6 
showed a decreased risk, while ERCC5 and RAD23B increased it (70). Furthermore, XPD and 
ERCC1 may be associated to poor disease free survival (DFS) in HNC, suggesting a significant 
role of NER in these tumours (71). 
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1.4.2. Cytogenetic alterations 
Malignant progression may be associated to particular chromosomal alterations. For instance, 
early changes at 3p, 4q, 8p, 9p, 11q, 13q and 17p have been observed in leukoplakias while loss 
of heterozygosity (LOH) of 9p21 is a common genetic event in oral premalignancies (72,73). 
Califano et at described a model of carcinogenesis in 1996, but it seems to be more the 
accumulation rather than the order of genetic events what determines tumoral progression (Figure 
8) (74).  
Amplifications/loss of heterozygosity 
Amplification in a variety of key genes have been described in HNC, such as of 3q, 3q24-qter, 
5p, 8q23-24, 11q13, 11q14-22, 18p, 18q11.2, and 19q among others (75, 76). The critical proto-
oncogene Cyclin D1 is amplificated within the 11q13 region and may be a marker of progression 
in primary HNC (77). Cyclin D1 overexpression has been reported in laryngeal carcinoma and 
might be implicated in regulating cell proliferation by the critical G1/S checkpoint (78). P63 is a 
p53 homologue and a potential oncogene in squamous cell cancer that has been found in the distal 
arm of 3q (79). 
 
 
Figure 8. Frequent cytogenetic alterations in head and neck cancer. 
 
Loss of chromosomes 3p, 5q, 8p, 9p, 18q and 21q are commonly identified as well, where loss of 
18q could indicate poor prognosis tumours (80). The most commonly deleted region in HNC is 
located at chromosome 9p21-22 (81). It occurs in the majority of invasive tumours and is present 
at a high frequency in early premalignant lesions, including dysplasia and carcinoma in situ (82). 
P16 or cyclin-dependent kinase inhibitor 2 (CDKN2-) is the tumour suppressor gene contained 
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within this critically deleted region and is a potent inhibitor of cyclin D1/CDK4 (83). However, 
p16 amplification is independent of cyclin D1 inactivation in HNC (84). It is possible that a second 
tumour suppressor gene resides at 9p21. In the same INK4 loci, an alternative reading frame 
codifies for a very different unrelated protein, p14ARF, which regulates MDM2 and therefore 
p53. Introduction of p16 or p14ARF into head and neck cancer cell lines results in potent growth 
suppression (85). Loss of heterozygosity (LOH) at the Retinoblastoma (Rb) locus in 13q14 has 
been found in around 14% of HNC, leading to Rb protein inactivation and tumour progression 
(86). Rb LOH is correlated with altered pRB expression in endometrial and oesophageal cancer (87, 
88) but same results could not be found for laryngeal cancer (89). 
 
1.4.3. TP53 
Mutations in P53 are one of the most frequent abnormalities in HNC and can be observed in 
severe dysplasia. TP53 mutations are found in 39-53% of HNC tumours and in 56.7% of laryngeal 
carcinomas (90, 91). P53 mutations have been demonstrated to be related to poor survival in different 
publications by using microarray technology (90), immunohistochemistry (IHC) (92) or single-
strand conformational polymorphism (SSCP) analysis followed by DNA sequencing. However, 
there is not necessarily correlation between IHC and SSCP results (91); moreover, decrease in 
survival can vary if the mutation is disruptive or non-disruptive (90). These controversies may 
explain differences as a prognostic factor found so far. 
 
1.4.4. Notch 
Inactivating mutations of Notch1 have been found in 10-15% of HNC, being the second most 
frequently mutated gene after TP53 (93,94). Notch signalling pathway has been linked to multiple 
biological functions, such as regulation of self-renewal capacity, cell cycle exit, and survival. In 
HNC, several of the Notch family mutations encode inactivating mutations, suggesting a tumour 
suppressor function (95). In a study that included 289 patients with laryngeal carcinoma Notch3 
was associated with unfavourable disease-free survival and overall survival (96). 
 
1.4.5. EGFR/EGFRvIII 
The EGFR pathway is involved in cell transformation through autocrine overproduction of 
epidermal growth factor/transforming growth factor alpha (EGF/TGFá) and overexpression of 
EGFR by gene amplification or altered transcriptional mechanisms (97). Production of TGFá and 
EGFR mRNA has been found in normal mucosa of patients at risk for a primary or secondary 
HNC suggesting these changes to be early markers of carcinogenesis (98). 
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In up to 90% of HNC, increased expression of EGFR is observed which is associated with 
advanced stage, poor survival and resistance to treatments (99, 100). Similarly, EGFR 
overexpression in laryngeal carcinoma has also been linked to poor survival (101) and also as a 
predictive biomarker for radiotherapy treatment (102). In a phase III trial comparing cisplatin with 
or without the monoclonal antibody cetuximab for metastatic/recurrent HNC patients, it was seen 
that doses of cetuximab may need to be adjusted for patients with very high levels of EGFR to 
achieve better response (103). The EGFRvIII mutant variant has been found in up to 40% of HNC 
and it seems to contribute to cancer growth and resistance to EGFR targeting. EGFRvIII is seen 
in cells that overexpress wild-type EGFR suggesting that mutations are a later event caused by 
rapid proliferation induced by EGFR overexpression (104). 
 
1.4.6. DNA damage repair biomarkers. MAP17 and pH2AX 
As laryngeal cancer responds to treatments based on platinum and radiotherapy that result in DNA 
damage, biomarkers implicated in the nucleotide excision repair (NER) and the double strand 
breaks repair might have a significant role. DNA Double break streams (DBS) can be originated 
by drugs and ionizing radiation but also by increasing the levels of reactive oxygen species (ROS) 
(105) through MAP17 activation. MAP17 is a small 17 Kda non-glycosylated membrane protein 
overexpressed in carcinomas.  It has been found present in adenoma and benign tumours, and is 
highly expressed in metastatic carcinoma. The expression is mainly driven at a transcriptional 
level either by promoter activation or demethylation. Expression of MAP17 in primary cells 
triggers senescence through p38, but in tumoral cells enhances the malignant capabilities of these 
cells, increasing proliferation, migration, resistance to apoptosis, etc. MAP17 expression 
increases the levels of ROS in cells which may account for some of the increased tumoral 
properties. In turn, a further increase of ROS might switch the balance towards apoptosis. Thus, 
MAP17 may increase the efficacy of therapies increasing ROS and therefore constitute a 
biomarker for better prognosis of these tumours. In cervix tumours treated with cisplatin and 
radiotherapy, high levels of MAP17 mark good survival of the patients. Therefore, MAP17 is not 
only a marker for stage and malignant status but also may be a marker of prognosis and response 
to therapies involving oxidative stress (106-108). DNA DBS lead to activation of three kinases, ataxia 
telangiectasia mutated (ATM), ATM-Rad3-related (ATR) and DNA-PK which phosphorylate 
γH2AX, a component of the histone octamer in nucleosomes. PH2AX is involved in recruiting 
DNA repair proteins in response to double-strand breaks (DSB) (108). Therefore, it is considered 
as a biomarker of DNA damage, as the presence and magnitude of pH2AX is an indication of 
persistent, unrepaired DNA damage. pH2AX induction appears within minutes in cells after DNA 
damage and reaches maximum levels after 30 minutes. The repair process includes the 
phosphorylation of hundreds to thousands γH2AX surrounding the DSB site in order to form a 
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focus that open the chromatin structure and serve as a platform for the accumulation of factors 
involved in the DNA damage response (109).  The NER pathway guard the integrity of the genome 
by recognizing and removing DNA cross-links caused by cisplatin or radiation mainly driven by 
the excision repair cross-complementation group 1 (ERCC1) (110). In locally advanced HNC low 
expression of ERCC1 was an independent predictor factor for prolonged in patients treated with 
cisplatin-based CCRT; however just 18% of patients had laryngeal carcinoma (111). Furthermore, 
in a case-control study focused on laryngeal cancer, ERCC1 rs11615 and ERCC5 rs17655 
polymorphisms were associated with increased risk of developing laryngeal cancer (112). 
 
1.4.7. Vaccinia-related kinase-1 (VRK1) protein 
VRK1 protein belongs to a family of three protein kinases implicated in regulation of cell 
proliferation by phosphorylation of p53 and cooperation with c-Jun and ATF2. VRK1 expression 
is activated by E2F and inhibited by p16 and Rb. In HNC, VRK1 could be a significant control 
mechanism of the cell cycle, particularly in G1-S phase (113). 
 
 
Figure 9. Mechanism of response to DNA damage in laryngeal cancer.  IR: ionizing radiation. 
 
1.4.8. STAT3 pathway 
Stat3 (signal transducer and activator of transcription 3) is a transcription factor that responds to 
cytokines and growth factor receptor activation (114). Constitutive activation of the pathway in 
response to deregulate upstream signals is commonly observed in diverse cancers including dead 
and neck and laryngeal tumours (115-117). This constitutive activation of the pathway has been 
involved in proliferation and survival of tumours as well as resistance to chemo and radiotherapy 
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(116,117). Recent works indicate that STAT signalling also contributes to therapy resistance by 
modulating also the microenvironment (118). ERp57 (GRP58) is a chaperone that regulated proper 
folding of glycoproteins (119). ERp57 is associated with tumour progression and has been described 
to modulate STAT 3 activity, thus regulating radioresistance in laryngeal cancer (120). 
Accordingly, ERp57 has been described as a poor prognosis factor. 
 
1.4.9. Micro RNAS 
MicroRNAs (miRs) play important roles in many pathological alterations regulating important 
cellular and physiological processes such as cell proliferation, differentiation, metabolism, 
apoptosis, autophagy and intercellular communications (121, 122). It has been considered that miRs 
regulate around 60% of genes in the human genome. The analysis of miR expression variation in 
Laryngeal cancer by a variety of techniques including broadly used miR microarrays and massive 
sequencing have shown a large variety of miRs deregulated in laryngeal cancer, many of them 
with diagnosis or prognosis value (reviewed in (123)) (124,125) (Table 4). These miRs behave as 
oncogenes (oncomirs) or tumour suppressors in laryngeal cancer according the effect of the target. 
However, this simplistic analysis is commonly more complicated since one miR can target several 
genes and several miRs can target the same gene thus providing some synergistic effects. 
Interestingly, several miRs have been associated with therapeutic resistance in laryngeal cancer, 
thus providing worse prognosis. 
 
MIRNAS TARGET PROGNOSIS 
UPREGULATED 
miR-16 Zyxin ND 
miR-19a TIMP2 Poor survival, Lymph node metastasis 
miR-21 BTG2 Poor survival, poor differentiation and 
Lymph node metastasis  
miR-27a PLK2 ND 
miR-106b RUNX3  Poor survival, poor differentiation and 
Lymph node metastasis 
miR-129-5p APC ND 
miR-155 SOCS1, 
STAT3 
Poor differentiation and TNM stage 
miR-1297 PTEN ND 
DOWNREGULATED 
miR-1 FN1 ND 
miR-24 S100A8 ND 
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miR-144-3p ETS-1 Poor prognosis 
miR-34a Survivin Good prognosis 
hsa-miR-
34c 
C-Met ND 
miR-126 Camsap1 ND 
miR-139 CXCR4 ND 
miR-203 ASAP1 Good survival , inverse to TNM and grade 
of differentiation. 
miR-206 VEGF Good survival , inverse to TNM and 
clinical stage. 
miR-299-3p hTERT ND 
miR-370 Fox-M1 ND 
miR-519a HuR, COX-
2 
ND 
miR-874 HDAC1 ND 
Table 4. Summary of miRNAs relevant in laryngeal cancer. Adapted 
from Yu and Li, 2015 [10]. ND: not determined 
 
1.4.10. Tumour microenvironment. Immune-phenotypes 
Most tumour cells express antigens that can mediate recognition by host CD8+ T cells. Cancers 
that are detected clinically must have evaded antitumor immune responses to grow progressively. 
HNC analysis of tumour microenvironment has revealed the presence of two major subsets of 
tumours with distinct mechanisms of resistance to immune-mediated destruction. 
The inflamed (and mesenchymal) phenotype present in a group of HNC tumours show prominent 
tumour infiltration by CD8(+) lymphocytes and a broad chemokine profile. This is independent 
of HPV status. Immune resistance occurs after T-cell migration into the tumour site, implicating 
the effect of negative immune regulators. On the other hand, the non-inflamed tumours are devoid 
of T cells and other indicators of innate immunity, such as chemokines. Immune failure is 
attributed to poor effector T-cell trafficking, as required factors are absent. These two major 
phenotypes of tumour microenvironment may require distinct immunotherapeutic interventions 
for maximal therapeutic effect (126). 
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1.5 LARYNGEAL CANCER TREATMENT 
	
1.5.1. Preservation approaches 
Organ preservation treatments for laryngeal cancer patients depend on whether the tumour is 
presented in early stages (I and II) or advanced locoregional disease (stage III/IV). In general, 
early stages are treated with either primary surgery or definitive radiotherapy (RT), while 
advanced stages require a multimodal approach. 
Early stage disease (Stages I and II)  
Total laryngectomy was the gold standard treatment by the 1980s with the subsequent loss of 
speech and airway patency. Because of the significant quality of life decreasing of these patients, 
partial laryngectomies and endoscopic laser surgeries were initiated in the 90´s in order to 
preserve laryngeal function. Furthermore, 95% local control rates have been described in patients 
with T3 and T4 glottic and supraglottic tumors who underwent supracricoid larynguectomy, with 
an associated improvement of quality of life (127,128).  
Later, radiotherapy was given to early stages. Although surgery and radiotherapy have never been 
compared in a randomized trial, both have been accepted to have similar effectiveness. This is 
based on one-arm prospective trials and prospective case-control series. In one of these series 
published in 2002, 31% locoregional control was reported for T3 laryngeal cancer with an organ 
preservation rate of approximately 50% (129). Alternative radiotherapy schedules were studied 
such as the hyperfractionated or the accelerated radiotherapies. Both techniques showed improved 
laryngectomy free-survival, and increased locoregional control compared to standard 
radiotherapy without increasing toxicity. However, none of them could show a benefit in terms 
of survival. The RTOG 90-03 phase III trial confirmed those results and demonstrates a better 
local control rate with hyperfractionated and accelerated radiotherapy compared to standard 
treatment (55% vs 45%) (130).  
Locally advanced (Stages III and IVA/B)  
Although functional organ sparing approaches permit larynx preservation, they do not provide a 
survival advantage over total laryngectomy (131). Three sparing approaches are accepted: RT, bio 
or chemotherapy with concomitant radiotherapy (B/CT RT) and induction CT (ICT) followed by 
RT with or without B/CT.  
CTRT with concurrent cisplatin showed higher preservation rates compared to other two arms 
with RT alone or induction cisplatin plus fluorouracil followed by RT (88% vs 70% and 75%, 
respectively) with similar two and five-year survival (132). Later, a 10-year follow-up publication 
		 	
42	
confirmed that the arms that included ICT improved laryngectomy-free survival (LFS). Contrary 
to preservation rates, LFS includes not just the need of salvage laryngectomy but also speech and 
swallowing quality. It is, therefore, more similar to what we currently understand as larynx 
preservation (133). A subsequent meta-analysis for locally advanced larynx cancer found that 
adding CT concomitant with RT led to a benefit of 6.5% absolute improvement in 5-year OS (134). 
In a phase III trial, patients with advanced head and neck cancer who received combination 
treatment with RT and cetuximab, demonstrated a statistically significant advantage with respect 
to locoregional control (LRC) and survival compared to patients treated with radiation alone (135). 
A subset analysis of the patients with hypopharyngeal and laryngeal tumors showed a 
preservation hazard ratio (HR) of 0.62 in the cetuximab arm but this was not statistically 
significant (136).  The optimal dose of cisplatin during RT remains still unclear. This was studied 
as a subset analysis of the RTOG 0129 phase III trial, which compared accelerated concomitant 
boost vs standard RT fractionation. Receiving one cycle of 100 mg/m2 cisplatin was associated 
with worse OS, PFS and locoregional failure compared to two and three cycles. The third dose of 
cisplatin had no impact on OS or PFS compared with two cycles, but was associated with better 
LRC rate (137). A meta-analysis presented in 2011 also suggested that there could be a 
dose/efficacy relation for concomitant cisplatin total dose. In this analysis, no advantage in OS 
was observed between CRT with cisplatin total dose <150mg/ m2 and RT alone. No difference 
in OS was observed between cisplatin high dose (300mg/m2) (HR 0.59, 95% CI 0.46-0.74) and 
cisplatin <300mg/m2 plus 5-fluorouracil (HR 0.59, 95% CI 0.45- 0.77) when compared to RT 
alone (138). Finally, a systematic review showed that in six definitive radiotherapy phase III trials 
there was a statistically significant association between cumulative cisplatin dose, and overall 
survival benefit for higher doses (139). In summary, two or three courses of three-weekly cisplatin 
could be considered the optimal dose for concurrent CTRT and equivalent doses of carboplatin 
have also been accepted by expert panels.  
Regarding ICT, the Veterans study demonstrated 64% preservation larynx rate without worsening 
survival in the ICT-RT arm compared with surgery-RT (63). More efficacious induction regimens 
were further developed and the docetaxel, cisplatin, and 5- Fluorouracil (DCF) schedule became 
the standard treatment, preserving the larynx 15% more than cisplatin and 5-Fluorouracil (140).  
DCF induction followed by radical RT with concomitant cetuximab or cisplatin showed similar 
larynx preservation rates in both arms in a phase II randomized trial. Endpoints were evaluated 
on the randomly assigned population only, which represented 76% of the patients included in the 
trial so they were inflated. None of the arms could show any substantial benefit compared with 
the GORTEC 2000-01 trial, and therefore there is still not evidence enough for sequential therapy 
in this setting (141)  (Table 5).  
		 	
43	
1.5.2 Metastatic disease (stage IVC)  
Despite treatment progress, locoregional recurrences and distant metastases occur in 20-30% of 
patients with SSCHN, and just few of them benefit from salvage surgery or re-irradiation. 
Treatment options for metastatic disease include supportive care, single agent or a chemotherapy 
combination with or without targeted agents (142). Prognostic factors of long-term survivors in 
metastatic SCCHN patients treated with platinum-based chemotherapy were identified in the 
E1395 and E1393 randomized trials of the Eastern Cooperative Oncology Group (ECOG) and 
include: tumour cell differentiation, ECOG performance status (PS), weight loss, location of the 
primary tumour and prior radiotherapy (143).  
The EXTREME trial showed that the combination of platinum-5Fluorouracil and cetuximab as 
first-line treatment in SSCHN improved OS, PFS and response rate with no decreased quality of 
life compared to the same schedule without the monoclonal antibody. Therefore, it has become 
the standard of treatment for patients with good PS (144). Less intensive schedules include de 
combination of cisplatin-paclitaxel or cisplatin-5Fluorouracil, as they have been shown to achieve 
similar overall survival (145). Other regimens such as cisplatin plus cetuximab improved response 
rate in a phase III trial but with no benefit of PFS which was the primary end-point (146). Single 
agent activity remains poor but it may be an alternative when other options are exhausted. 
Classical drugs as methotrexate, cisplatin, 5-fluorouracil (5-FU) and bleomyin have shown 
responses of short duration (3-5 months) and 15-30% tumour reduction (142). Of the more recent 
agents, taxanes (docetaxel and paclitaxel) improved response rates up to 43% in platinum resistant 
patients (147). Furthermore, afatinib is an irreversible ERBB family blocker with significant results 
in the second-line setting. In a recent phase III trial it was compared to methotrexate in patients 
that had progressed to platinum-based regimens (including also cetuximab) and the primary end-
point PFS was superior (2.6m vs 1.7m, p=0.03). However, G3/4 toxicities were also higher in the 
afatinib arm (148). Finally, different immunotherapies agents are being studied for HNC. Of them, 
nivolumab is the most advanced as the final results of the phase III trial have been recently 
published. Patients after relapse or progression within 6 months of platinum therapy were 
randomized to biweekly nivolumab vs dealer´s choice. The primary outcome was overall survival 
which was 7.5 vs 5.1 m with a 95% IC. Moreover, at the time of analysis, 17.4% were still 
receiving nivolumab 2.7% were still receiving standard therapy. Although there is still a need for 
biomarker validation and patient selection, nivolumab could be considered as a new standard of 
care for second line treatment HNC (149).  
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HYPOTHESIS, OBJECTIVE AND ENDPOINTS OF THE STUDY 
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2.1. HYPOTHESIS 
There are different organ preservation treatments available for patients with non-metastatic 
laryngeal cancer. Because these regimens can maintain laryngeal function, are generally preferred 
to surgery. On the other hand, no benefit on survival has been determined with preservation 
approaches, and they confer significant acute and late toxicities. Furthermore, around 30-40% of 
patients relapse or lead to an incompetent larynx and might end having surgery (63).  
The high rate of toxicities and non-improved survival with preservation approaches lead to the 
need for biomarker development. Predictive larynx biomarkers would facilitate pre-treatment 
identification of those patients who are unlikely going to be cured by radiation-based therapy. By 
managing these patients with surgery rather than a preservation approach, local disease control 
and possibly survival could potentially be optimized and unnecessary treatment related 
morbidities from unsuccessful larynx treatments could be avoided.   
 
2.2. GOAL 
With this study we aim to find clinical and/or biological biomarkers that could be related with a 
better prognosis and potentially be used as predictive biomarkers for pre-treatment patient 
selection.  
	
2.3. ENDPOINTS 
2.3.1 Primary endpoint 
To determine whether molecular biomarkers such as MAP17 and PH2AX are associated to 
survival in patients with non-metastatic laryngeal cancer treated with preservation approaches.  
2.3.2 Secondary endpoints 
-To determine clinical factors implicated in survival and laryngeal preservation. 
-To determine whether molecular biomarkers are associated to laryngeal preservation. 
-To study the correlation between clinical and biological biomarkers and their relationship with 
survival.  
-To study the role of the DDR pathway in laryngeal pathway and patient´s survival.  
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 MATERIALS AND METHODS  
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3.1 PATIENT´S CHARACTERISTICS AND TREATMENT 
We evaluated 65 patients with larynx cancer from August 2005 to February 2014. However, out 
of the 65 tumoral samples, only 53 of them could be studied. All samples were obtained from 
diagnostic biopsies before treatment. All patients completed the informed consent form and the 
project was approved by the local ethical committee at the Hospital Universitario Virgen del 
Rocío (HUVR) (PI13/059). Patients received treatment in our institution but tumour samples were 
obtained from four different national hospitals where the diagnosis was made. Eligibility criteria 
for treatment preservation include patients with stage II-IV laryngeal tumours that had no 
contraindication for CT or RT, significant cartilage destruction, or more than 2 cm tumoral 
invasion of the base of the tongue. TNM Staging System (7th ed., 2010) was used for tumour 
classification (27). Patients were mainly male (94%) with squamous cell carcinoma and good 
general condition. Tumours were more frequently localized in the supraglottic (60%) and 75.5% 
were stage III. Approximately one third of patients required pre-treatment tracheotomy. Selected 
organ preservation therapies were B/CTRT (75%), RT (14%), or ICT-B/CTRT (9%). Cisplatin 
100 mg per square meter (m2) on days 1, 22, and 43 (74%) was most commonly used, followed 
by weekly cisplatin 40 mg/m2 (11%), and monoclonal antibody cetuximab (11%) (Table 6). 
  
 
 
 
 
 
 
 
	
	
	
	
	
 
 
Table 6. Population characteristics and treatment. 
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3.2 TISSUE ACQUIREMENT AND PREPARATION 
Formalin-fixed, paraffin-embedded tissue sections from 65 laryngeal carcinomas were selected 
with the collaboration of the Andalusian Health Care Biological Resource Centre. Histological 
characterization of all samples was done by Hematoxylin and Eosin staining, followed by 
immunohistochemistry (IHQ) analysis of tissue microarrays (TMA). 
 
3.2.1 Immunohistochemistry 
Three-micrometer slices were sectioned from the TMA block and applied to coated, 
immunochemistry slides (DAKO, Glostrup, Denmark). The slides were baked overnight in a 56°C 
oven, deparafinized in xylene for 20 min, rehydrated through a graded ethanol series and washed 
with PBS. A heat-induced epitope retrieval step was performed by heating a slide in a solution of 
sodium citrate buffer pH 6.5 for 2 min in a conventional pressure cooker. After heating, the slides 
were incubated with proteinase K for 10 min and rinsed in cool running water for 5 min. 
Endogenous peroxide activity was quenched with 1.5% hydrogen peroxide (DAKO) in methanol 
for 10 minutes, and incubation with the primary antibodies was performed for 40 min. Selected 
antibodies were: anti-gamma H2A.X (phospho S139) antibody (ab11174 from Abcam), anti-p53: 
p53 FL 393 (sc-6243 from Santa Cruz), anti-MAP17 (1:4) [29-33], anti-SGLT1 (Abcam #14685), 
ki67 (clone MIB-1; DAKO, Agilent technologies, United States), AKT-p (phosphorylated S473-
AKT1, Epitomics), and p44/p42 MAPK (Erk1/2) Rabbit mAb 1:1000 (Cell Signaling 137F5). 
After incubation, immunodetection was performed with the EnVision (DAKO, Glostrup, 
Denmark) visualization system using diaminobenzidinechromogen as the substrate, according to 
the manufacturer’s instructions. Immunostaining was performed in a TechMate 500 automatic 
immunostaining device (DAKO) and measured through a double- blind visual assessment using 
microscopic observation according to the anatomopathological experience of pathologists. 
Sample scoring was performed by semiquantitative microscopic analysis, considering the number 
of stained cells (percentage of positive cells) and signal intensity (levels 1, 2, or 3). 
 
3.3. CELL CULTURE FOR IN VIVO RADIATION TREATMENT 
Hela malignant cervical tumour cells were obtained from the European Collection of Cell 
Cultures (ECACC) human cell line repository and maintained in Dulbeccós modi ed Eaglés 
medium (Sigma) containing 10% fetal bovine serum (Sigma), penicillin, streptomycin and 
fungizone. MAP17 full-length cDNA was cloned into pBabepuro and mass culture generated by 
stable gene transfer in Hela cells. After selection with 2 ìg/ML puromycin, mass cultures were 
used for the study. As a control, Hela cells were transfected with pBabepuro alone and selected. 
Cells were irradiated using Costar 24 well cell culture plates (Corning Incorporated, NY USA). 
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To simulate actual radiobiological experimental conditions, each well was filled with culture 
medium. The plate dimensions were 12.5 x 8.5 cm. The inner diameter of the well was 16 mm 
and the distance between the centers of two neighboring wells was 20 mm. Plates were positioned 
inside a water-equivalent device, specifically designed to fit the plate. This device measures 16 x 
16 x 2 cm, and is placed inside the IBA BodyPhantom (IBA Dosimetry GbmH, Schwarzenbruck, 
Germany) at a depth of 6 cm. Simulation was performed using a Toshiba Aquilion CT scanner 
(Toshiba Corporation, Japan). CT images were exported to the treatment planning system Philips 
Pinnacle V9.2 (Philips Radiation Oncology Systems, Madison, WI). Five plans were designed to 
deliver uniform doses of 0.1 Gray (Gy), 0.3 Gy, 1 Gy, 3 Gy and 10 Gy using static beams of 24 
x18 cm. To verify the dose within every well, we delineated 24 regions of interest (ROI) that had 
a diameter of 16 mm. The ROI was estimated at the bottom of the wells and 5mm upwards. The 
dose delivered to the cells was verified with the IBA Compass system (IBA Dosimetry GbmH, 
Schwarzenbruck, Germany). Differences between the prescribed dose and the dose received were 
within 3%. The irradiation was delivered using 6 megaelectronvolts (MV) photon beams from an 
Elekta Synergy Linac (Elekta Oncology System, Ltd, Crawley, UK) with a dose rate of 500 
mu/min.  
 
3.4. STATISTICAL ANALYSIS AND DEFINITIONS 
Kaplan-Meier method was used for survival analysis, using Cox Proportional Hazards model to 
adjust for the explanatory variables, obtain the p-values and estimate the hazard ratios (HR). 
Multivariate logistic regression was used to obtain odds ratio (OR) and CI 95%. Pearson’s 
correlation measured dependence between quantitative variables. A receiver operating 
characteristic (ROC) curve was performed to assess the biomarker cut-off point (two-year OS for 
pH2AX and three-year OS for MAP17), which was confirmed using the optimal Youden index-
based point. In addition, the log-rank test was used to compare survival distributions. Categorical 
data were studied with contingency tables that included Chi-square statistics. Calculations were 
performed using SPSS 15.0 software. OS has been defined as the length of time from diagnosis 
until the last medical record. Locoregional control (LRC) was measured as length of time from 
diagnosis until the relapse or last medical record, in those patients who did not develop distant 
metastases or died due to different causes than the tumour. For laryngoesophageal dysfunction-
free survival (LDS) we adopted Lefebvre Larynx Preservation Consensus Panel that included as 
endpoint events: death, local relapse, total or partial laryngectomy, tracheotomy at two or more 
years, or the presence of a feeding tube at two or more years (150). 
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                        Figure 10. Example of ROC curve to determine the cut-off point for pH2AX. 
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4.1. MAP17 (PDZKIP1) AS A NOVEL PROGNOSTIC BIOMARKER FOR LARYNGEAL 
CANCER 
 
MAP17 is a small 17 Kda membrane protein present in carcinoma, but also in adenoma and 
benign tumours, and is highly expressed in metastatic carcinoma. Its expression correlates with 
staging and malignant status of the tumour. MAP17 expression is associated with an SGLT-
dependent ROS increase that acts as a second messenger enhancing tumorigenesis. While a mild 
increase in ROS has been shown to activate signalling cascades that upregulate tumorigenic 
processes, further ROS increases lead to a potentially toxic cellular environment and programmed 
cell death. The hypothesis is that tumours expressing high levels of ROS producing MAP17 and 
SGLT1 proteins can benefit from therapies such as cisplatin or radiotherapy that increase 
oxidative stress and could sensitize them to cell death. In this work we have explored the relevance 
of the presence of MAP17 in larynx tumours where primary response is mainly achieved by 
treatments with radiotherapy and platinum compounds or other radiosensitizers.  
 
4.1.1. Clinical cohort description 
Lymph node metastases were significantly associated with decreased OS (N0 63.1 m, N1 38.6 
and N2 22.2 m, p=0.019) while tumour local extension impacted LDS negatively (T4 extension 
7.3 m vs. 47.1m non T4 extension, p=0.003). Besides, patients who required pretreatment 
tracheotomy had significantly worse LDS (54.3 vs. 18.9 months, p=0.001). The two-year 
cumulative proportion of patients with larynx preservation and OS were 57% and 76% 
respectively. Besides, locoregional control rate at two years was 60%, so similar to previously 
reported in the literature (section 1.5.1).  
 
4.1.1. MAP17 expression in larynx tumour samples  
Out of 65 samples, only 58 were analysed for MAP17 expression, either due to technical problems 
or because they did not contain any tumour cellularity. Out of the 58 samples, 46 (79%) were 
positives for MAP17 expression (Figure 11 A, B and C) and there was a trend showing higher 
levels of MAP17 in advanced grades of the tumour (Figure 11 D), although in this case, probably 
due to the low number of cases, it was not statistically significant. Surrounding normal tissue did 
not express MAP17 or expressed very low levels. We also analysed other markers for 
proliferation such as KI67 or the activated form of ERK (phosphorylated ERK, ERK-p), or 
apoptosis such as mutant p53 or activated AKT (phosphorylated AKT, AKT-p). Our cohort 
showed a percentage of samples positive for KI67, mutant p53, ERK-p or AKT-p, but these 
groups did not show correlation with MAP17 levels (Figure 12). However, KI67 positivity 
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showed statistically significant correlation with OS (Table 7). No correlation of MAP17 was 
observed with clinical parameters such as tumour localization, smoking habit, alcohol 
consumption, tumoral stage, pre-treatment tracheotomy and development of acute toxicities 
during chemoradiotherapy.  
 
 
 
Figure 11. MAP17 overexpression in larynx tumours. A) Representative images of MAP17 immunostaining 
are shown for different larynx tumours. B) High magnification of M17 positive and negative tumours. The 
picture shows a magnification of the inset of figure A. C) A graph is shown representing the percentage of 
laryngeal tumours with dichotomous MAP17 levels. The score for positive tumours were >62. D) The 
distribution of the MAP17 expression levels among different grades of larynx tumours is shown. The 
MAP17 levels (score) refers to maximum levels (0–2) scored by the percentage of cells (0–100). The 
normalized levels were obtained by multiplying the percentage of cells by the level of intensity observed. 
Anova test was performed to establish the statistical association between MAP17 protein levels and the 
grade of the tumour (p<0,05). 
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Table 7. Laryngoesophageal dysfunction-free survival (LDs) and overall survival (Os) multivariate 
analysis of laryngeal cancer patients treated with preservation approaches. Pret. Tracheo.: pretreatment 
tracheotomy required. PS: ECOG-performance status. B/CTRT: bio/chemoradiotherapy; ICT-B/CTRT: 
induction chemotherapy followed by bio/chemoradiotherapy. 
 
 
 
Figure 12. p53, Ki67, p-ErK or p-AKt do not show correlation with MAP17 expression in larynx 
tumours. A) Representative images of p53, Ki67, p-ERK or p-AKT immunostainings are shown for larynx 
tumours. B) Graphs showing lack of correlation between these proliferative or antiapoptotic markers and 
MAP17 expression. 
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4.1.2. SGLT1 overexpression in human larynx tumours correlates with MAP17 levels  
Previous results indicated that MAP17-dependent tumorigenic properties depend on the indirect 
activation of ROS by SGLT1 transport and that there is a correlation between the expressions of 
both markers in cervix tumours (107). Therefore, we measured SGLT1 expression levels in the 
same cohort of larynx tumour samples. We found that some tumours showed positive SLGT1 
staining, with approximately 40% tumours being positive for SLGT1 (Figure 13 A, B, C and D). 
However, only a few samples showed very high staining levels. The distribution of the SGLT1-
positive tumours among the different larynx tumours showed a clear correlation with MAP17 
expression (Figure 13 E, F and G). Pearson indicator expressed a positive significant correlation 
between MAP17 and SGLT (P=0.3, p=0.022). 
 
 
Figure 13. SGLT1 overexpression in larynx tumours. A) Representative images are shown of SGLT1 
immunostaining of different larynx tumours. B) High magnification of SGLT1 positive and C) Negative 
tumours. D) Graph representing the percentage of larynx tumours positive or negative for SGLT1 
expression. E) Graph representing the correlation between MAP17 and SGLT1 expression in each tumour. 
The statistical analysis was performed by Pearson correlation (p=0,0022). F) Samples from one patient 
showing clear correlation between the expression of MAP17 and SGLT1. G) High magnification of samples 
from one patient showing clear correlation between the expression of MAP17 and SGLT1. 
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4.1.3. MAP17 as predictive biomarker for laryngeal cancer  
The high MAP17 group correlated in this study with better OS, LDS and LRC. When MAP17 
was measured as a continuous variable, multivariate Cox model demonstrated that higher rates of 
MAP17 levels correlated with improved OS (HR 0.98, p= 0.001). Nevertheless, this could not be 
confirmed for LDS (HR 0.99, p=0.8), probably due to the limited number of cases. In order to 
distinguish a cut-off point for MAP17 levels a ROC curve was performed and punctuation of 62 
score chosen. When measured as a dichotomous variable, high-MAP17 was related with increased 
OS, LDS, and LRC. A difference of 35.3 months was observed between high-MAP17 levels (67 
months) and low-MAP17 levels (31.7 m) in the Kaplan- Meier model (IC 95%; p<0.001) (Figure 
14) and the HR estimator for high-MAP17 was 0.78, p=0.002 in the multivariate analysis. 
Regarding LDS, high-MAP17 showed a survival benefit of 13.1m (47.6 m vs. 34.5 m, p=0.002) 
with a HR 0.14, p=0.003 in multivariate analysis. The effect of MAP17 high levels on the 
improved survival was significant after controlling for other variables: P53, Ki67, SGLT, PS, 
TNM, pretreatment tracheotomy and treatment received as shown in table 7. Regarding LRC, 
patients with high-MAP17 showed to have better outcomes than low-MAP17 (53.9 m vs 44.5 m, 
p=0.016) and the results were confirmed in the multivariate model (p=0.045). However, although 
MAP17 correlated with SGLT in the Pearson model (Figure 13E), SGLT by itself did not show 
statistically significant correlation with OS or LDS. Moreover, the association of high-MAP17 
and high-SGLT show improved OS than MAP17 alone (72.4 m vs 42m, p=0,028) (Figure 14D). 
These data confirm that MAP17 alone, or preferably combined with SGLT1, is a good prognostic 
marker for survival in patients with larynx cancer treated with B/ CTRT.  
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Figure 14. MAP17 alone or in combination with SGLT1 are good independent markers for patient survival. 
A) Correlation of MAP17expression measured as a dichotomous variable, MAP17 high rates (>62) with 
overall survival. B) Correlation of MAP17 expression measured as a dichotomous variable, MAP17 high 
rates (>62) with laryngoesophageal dysfunction-free survival. C) A Kaplan-Meier curve is shown 
indicating that MAP17 could be a good prognostic marker for overall survival in laryngeal tumour patients 
treated with radiotherapy plus bio/chemotherapy. D) A Kaplan-Meier curve shown indicates that combined 
high levels of MAP17 and SGLT1 levels are a good prognostic marker for survival in laryngeal tumour 
patients treated with radiotherapy plus adjuvant chemotherapy. 
 
4.1.4. Tumour cells overexpressing MAP17 are more sensitive to radiation  
To explore whether MAP17 may be causal in this response, we expressed MAP17 cDNA in Hela 
cells and subjected these cells and their parental expressing only empty vector, to different doses 
of radiotherapy. Our data showed that Hela cells expressing MAP17 (Figure 15A) were more 
sensitive to radiation than parental cells without MAP17 (Figure 15B), therefore confirming the 
causal role of MAP17 in the sensitivity to radiation. Finally, to test our initial hypothesis of the 
relevance of ROS in the MAP17-enhanced radiosensitivity of Hela cells, we treated the cells with 
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antioxidants GSH and NAC, and subjected these cells to different radiation doses. We observed 
that both antioxidant treatments reduced the sensitivity of MAP17-expressing Hela cells to a 
range similar to parental cells, which remains mostly unaltered (Figure 15C and D).  These data 
confirm the relevance of the oxidative status of the tumours in the response to radiation.  
 
Figure 15. MAP17 overexpression in Hela cells induces sensitivity to radiotherapy. A) Hela 
cancer cells expressing ectopic MAP17 cDNA were selected and analysed for MAP17 mRNA 
expression by quantitative RT-PCR. B) Hela cells expressing ectopically MAP17 cDNA (Hela-
Map17) and parental cells expressing only empty vector (Hela) were seeded at equal 
concentration and subjected to different radiation doses as indicated, in triplicate samples. 48 
hrs after treatment the percentage of survival cells was measured in each case and plotted in the 
graph. The experiment was performed three independent times in triplicate. C and D) Hela cells 
expressing ectopically MAP17 cDNA (Hela-Map17) and parental cells expressing only empty 
vector (Hela) were seeded at equal concentration and subjected to pre-treatment with 10 mM 
GSH (C) or 10 mM NAC (D) during 18 hrs, then treated with different radiation doses as 
indicated, in triplicate samples. 48 hrs after treatment the percentage of survival cells was 
measured in each case and plotted in the graph. 
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In summary, our analysis in laryngeal cancer showed a significant relationship between high 
MAP17 protein expression and increased OS, suggesting that MAP17 expression is an 
independent biomarker for survival. In fact, high MAP17 levels demonstrated better OS than low 
levels (67 months vs. 31.7 months, IC 95%; p<0.001). High MAP17 showed better LRC and LDS 
as well. In addition, the associated high levels of MAP17 and SGLT showed improved OS, better 
than MAP17 alone. Finally, proof of principle experiments in vitro demonstrated that antioxidant 
treatments reduced the sensitivity of MAP17- expressing Hela cells to a range similar to parental 
cells, confirming the relevance of the oxidative status of the tumours in the response to radiation.  
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4.2. PHOSPHORYLATION OF GH2AX AS A NOVEL PROGNOSTIC BIOMARKER FOR 
LARYNGOESOPHAGEAL DYSFUNCTION-FREE SURVIVAL 
 
γH2AX is a component of the histone octamer in nucleosomes that its phosphorylated (pH2AX) 
by ataxia telangiectasia mutated (ATM), ATM-Rad3-related (ATR) and DNA-PK. PH2AX is 
involved in recruiting DNA repair proteins in response to the presence of DNA DSB. Therefore, 
it´s increasing is related to DNA damage and has been studied as a potential biomarker. Our goal 
was to determine whether pH2AX by itself or in combination with other molecular and clinical 
findings could be a prognosis biomarker for our cohort of laryngeal cancer. 
 
4.2.1. Clinical cohort description 
At the time of the analysis, 20 (32%) deaths and 29 (46%) recurrences had occurred with a median 
follow-up of 29m. Locoregional relapse occurred in 19 (30%) patients, 7 (11%) presented 
locoregional plus distant metastases, and 3 (4.8%) only distant metastases; of them, 14 (48.3%) 
were candidates for salvage surgery. Laryngoesophageal dysfunction (LD) occurred in 51% of 
the total; main reasons for LD were tumoral local recurrence (75%) followed by the need of a 
tracheostomy of feeding tube (15.6%). Mean OS was 58 m (47.7-68 m, CI 95%), LDS 46 m (36-
55.5m, CI 95%), and LRC 54.6 m (44-65 m, CI 95%), with a 2-year LRC of 63%. The 2-year 
cumulative proportion of patients with larynx preservation and OS were 57% and 80% 
respectively. Lymph node involvement was associated with worse OS (N0: 64.2m vs N1/2: 26.8 
m, p<0.01) but not with LDS (46.8 vs 24.6, p=0.6) (Figure 16B and A). Tumour local extension 
impacted negatively on both OS and LDS (OS non-T4 60.7 m vs T4 22.5 m; LDS non-T4 48.5 m 
vs T4 7.3m, both p=.001) (Figures 16D and C). Furthermore, patients who required pretreatment 
tracheotomy (PT) had worse OS (37.2 m vs 61.8 m, p=0.051) and LDS (19.6 m vs 55.4m, 
p=0.001) (Figures 16F and E).  
 
4.2.2. Cisplatin and radiotherapy as prognostic markers in larynx cancer 
As per the RTOG 0129 phase III clinical trial results (137), patients were classified by the dose of 
cisplatin received during the radiation treatment. In total, 52.4% reached the optimal dose of 
cisplatin during radiotherapy, whereas 17.5% could not reach the cisplatin optimal dose, 12.7% 
did not receive any radiosensitizer, and 14.3% were treated with other radiosensitizers. 3.1% were 
unknown. Cisplatin optimal dose (≥200 mg/m2) was associated with better survival, although this 
was statistically significant just for LDS (OS: 67 m vs 39 m, p=0.073; LDS: 56m vs 24 m, p= 
0.017; LRC: 60.4 m vs 29 m, p= 0.12) (Figures 17B and A). Receiving an optimal dose of cisplatin 
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had better LDS (p=0.023) than lesser doses (HR=0.24), other radiosensitizers (HR=0.32), and no 
concurrent radiosensitizers (HR=0.65). However, this benefit was not observed for OS probably 
because the analysis did not take into account patients that needed salvage laryngectomy and did 
not preserve the organ.  
Total dose of radiation delivered was 70 Gy, as per standard local guidelines. Patients that 
completed radiotherapy within 8 or 9 weeks were compared to those that suffered interruptions 
or delays but no differences were found in terms of OS or LDS between groups (Figure 18). 
 
 
Figure 16. A. and B. N0 compared with N positive LDS/OS. OS was better in the patients who had no lymph 
node involvement. C. and D. T4 local tumour extension shows worse OS and LDS than the rest of patients. 
E. and F. worse LDS and OS is observed in patients who required pretreatment tracheotomy (PT). 
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Figure 17. A. and B. Cisplatin (Cpt) optimal dose (≥200 mg/m2) showed significant LDS bene t that was 
not maintained for OS. 
 
4.2.3. pH2AX in larynx tumour samples 
Only 53 samples were analysed for pH2AX expression either due to technical problems or 
because they did not contain any tumour cellularity. Positive pH2AX expression, considered as 
any percentage of tumoral nuclei with positive staining, was shown in 46 (86.8%) samples with 
a range of 1 to 70 and median expression of 10 (figure 19A). In order to distinguish a cut-off point 
for pH2AX levels a ROC curve was performed and punctuation of 5.25 score chosen. Levels of 
pH2AX were equally distributed among tumour grades (Figure 19B) suggesting independence 
from this clinical feature, as the Chi-square test showed no differences between groups (p=0.8).  
When measured as a continuous variable, pH2AX had a significant positive influence with better 
LDS outcomes (HR 0.95, p=0.02), although this was not significant for OS. As a dichotomous 
variable, a trend towards better OS, LDS and LRC was observed but just LDS was statistically 
significant in the multivariate analysis (HR 0.26, p=0.02) (Table 2) (Figures 19C, D and E). 
We also studied the potential correlation between pH2AX and clinical findings such as tumour 
localization, tumoral stage, smoking habit, alcohol consumption and acute toxicity development 
with no statistically significant association. These results suggest pH2AX to be an independent 
prognostic factor, as it remains significant after controlling for these variables.  
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Figure 18. A. and B. No differences were found for radiotherapy delivered within less than 9 weeks or ≥9 
weeks in terms of LDS or OS. C and D. Same results for a cut-off of 10 weeks. 
 
 
 
Table 8. LDS and OS multivariate analysis. PT: pretreatment tracheotomy. N: pathological lymph nodes. 
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Figure 19. A. Positive pH2AX expression, considered as nuclei staining was shown in 46 (86.8%) samples. 
B. Levels of pH2AX are equally distributed among tumour stages. C., D. and E. high-pH2AX show a trend 
towards better OS, LDS and LRC not statistically significant in the Kaplan-Meier analysis. 5.25 as 
indicated by the ROC curve were used as cut-off for defining high and low expression of pH2AX for survival 
analysis. 
 
 
4.2.4. pH2AX relationship with cisplatin and radiotherapy 
The total dose of cisplatin was not associated with pH2AX levels (p=0.4). We created a variable 
with two categories from pH2AX and cisplatin, in which one had a potential favourable prognosis 
(high-pH2AX levels, and optimal dose of cisplatin, ≥200 mg/m2), and the other unfavourable 
prognosis (low-pH2AX levels, and/or suboptimal dose of cisplatin <200mg/m2 or other 
radiosensitizers due to the low number of patients). The favourable prognosis group correlated 
with increased OS, LDS (OS: 72 m vs 38.6 m, p=0.03; LDS 66.9 m vs 27 m, p=0.019). LRC was 
not statistically significant (p=0.17) although there was a trend towards better outcomes in the 
good prognostic subgroup (69.9 m vs 35.1 m) (Figures 20A, B and C). Moreover, the 
unfavourable prognosis group correlated with worse OS (HR= 3.66, p=0.044), and LDS (HR= 
3.38, p=0.028). LRC has a not statistically significant HR (HR=2.4, p=0.188). We also tried to 
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stablish whether high-pH2AX and no radiotherapy delays could impact on survival but no 
differences were found for both OS and LDS. 
 
4.2.5. Correlation of pH2AX with p53 and KI67 
We also analysed other markers for proliferation such as KI67 or the activated form of ERK 
(phosphorylated ERK, ERK-p), and apoptosis such as mutant (m) p53 or activated AKT 
(phosphorylated AKT, AKT-p). Our cohort showed a percentage of positive samples for ERK-p 
or AKT-p, but these groups did not show correlation with pH2AX expression (data not shown). 
KI67 in combination with pH2AX was not significant in any combination (data not shown), being 
pH2AX also independent of the proliferative capability of the tumour. Our results showed no 
correlation between p53 and pH2AX although there was a relation towards increased pH2AX 
with negative P53 (<5% positive nuclei) that was not statistically significant (p=0.33). 
However, in our cohort p53 samples positive (measured as >5% positive nuclei) (Figure 21A, + 
p53) correlated with worse OS (- p53=50 vs + p53=35.6 m, p=0.05) (Figure 21B) consistent with 
previous literature (151). 
P53 and pH2AX were combined into a new variable with the following categories: potential good 
prognosis phenotype (negative p53 and high-pH2AX) and unfavourable prognosis phenotype 
(positive p53 and low-pH2AX). Although there was an apparent relation towards better outcomes 
in the good prognosis phenotype, this was not significant for both OS and LDS (OS: 48.6 m vs 
39 m, p=0.39; LDS: 38.8 m vs 24.4 m, p=0.068) (Figures 21C and D). 
 
 
Figure 20. A., B. and C. pH2AX and dose of concomitant cisplatin were combined in a new variable where 
high-pH2AX and cisplatin (Cpt) ≥200 mg/m2 was considered as good prognosis phenotype category. The 
results show improved OS and LDS in this subgroup, and a trend towards better LRC. 5.25 as indicated by 
the ROC curve were used as cut-off for defining high and low expression of pH2AX for survival analysis. 
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Figure 21. A. P53 was measured as >5% positive nuclei, as shown in the picture. B. positive P53 (+ P53) 
correlates with worse OS in our cohort. C. and D. results of the combination of P53 and pH2AX in a new 
variable. Although there was a trend towards better outcomes in the good prognosis phenotype which 
included negative P53 (-P53) and high-pH2AX, this was not statistically significant for OS and LDS. 
 
4.2.6. Correlation of pH2AX and MAP17 
As discussed before, MAP17 increases endogenous ROS, which is a well-known mediator of 
DNA damage. Therefore, we measured whether pH2AX correlated with MAP17 expression and 
if the combination of both markers could strength the predictability of responses. We found that 
patients with high levels of MAP17 and subject to optimal doses of cisplatin had better LDS (58.6 
m vs 32.6 m, p=0.053) and OS (76.2 m vs 40.9 m, p=0.005) than patients with low MAP17 or not 
subject to optimal doses of cisplatin (Figures 22A and 7B). Furthermore, patients with high levels 
of MAP17 and high-pH2AX, denoting higher structural DNA-damage, conformed the group of 
better prognosis after therapy (Figures 22C and 7D). 
Moreover, patients with high-MAP17, high-pH2AX and optimal dose of cisplatin had better OS 
and LDS than the rest of the population (Figures 22E and F), and also when compared with 
patients having a poor prognosis phenotype (low-MAP17, low-pH2AX and suboptimal cisplatin 
dose) (Figures 22G and H). 
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In summary, these results show that pH2AX has a prognostic role in patients with laryngeal 
cancer. pH2AX was related to LDS (High- pH2AX HR 0.26, p = 0.02) in a cohort of 53 patients 
with larynx cancer. When analysed together pH2AX expression and dose of cisplatin received 
during radical treatment, there is a significant correlation with survival (high-pH2AX and optimal 
dose of cisplatin 72 vs 38.6 m, p = 0.03) and LDS (high-pH2AX and optimal dose of cisplatin 
66.9 vs 27 m, p = 0.019). Also, patients with high-MAP17 and high-pH2AX showed to have 
better OS and LDS. Our data also show the importance of performing optimal cisplatin treatment 
for tumour response. However, the fact that unexpected radiotherapy delays and interruptions did 
not affect survival in our cohort could be explained to dose compensations. Radiobiological-based 
calculations were performed in those patients in order to achieve an equivalent biological 
effectiveness by adding some more fractions to the overall treatment. Our data suggest that 
inherent DDR pathway activation (measured by the end-point of phosphorylation of H2AX) is a 
valuable prognostic marker in patients with laryngeal carcinoma who received organ preservation 
approaches.  
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Figure 22. A. and B. the combination of high-MAP17 and optimal doses of cisplatin (Cpt) showed better 
OS and LDS. C. and D. patients with high-MAP17 and high-pH2AX with higher structural DNA-damage 
showed to have better OS and LDS. E. and F. survival for patients with high-pH2AX, high-MAP17 and 
optimal dose of cisplatin was statistically better. G. and H. the subgroup of patients with high-pH2AX, 
high-MAP17 and cisplatin optimal dose patients was compared to the patients that had low-pH2AX, low-
MAP17 and did not complete cisplatin. Although limited in numbers, none of the patients with poor 
prognosis phenotype reached more than 2-years LDS or more than 3-years OS. 
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In this work novel biomarkers for patients diagnosed of laryngeal cancer who were candidates for 
organ preservation treatments have been identified. In general, accepted organ sparing approaches 
include radiotherapy, bio or chemotherapy with concomitant radiotherapy and induction 
chemotherapy followed by radiotherapy with or without bio/chemotherapy. To date, there are no 
biomarkers validated that could predict survival or response with these preservation approaches, 
and a number of patients have significant late toxicities or finally relapse. In those cases, salvage 
surgery can sometimes be performed. Identifying predictive biomarkers in this setting could avoid 
unnecessary toxicities and could potentially improve survival because of the better selection of 
patients.  
Pathological, clinical and therapeutic features of our population were studied in order to determine 
whether they could be related to survival. In this regard, patients with T4 primary tumour and 
those who needed a pre-treatment tracheotomy had worse LDS and seemed not to benefit of 
preservation treatments. Moreover, receiving optimal platinum total dose can determine LDS, as 
patients unable to complete treatment have a worse prognosis.   
A panel of different markers were studied in our population; proliferation markers such as Ki67 
or p-ERK, apoptosis such as p53 and p-AKT. However, DNA damage response biomarkers such 
as MAP17, SGLT and pH2AX were the ones implicated with survival in our cohort.  
MAP17 is a membrane-associated protein known to increase endogenous ROS through SGLT1 
in cancer cells (152,153). ROS are well known mediators of DNA damage. In a previous study, 
expression of both MAP17 and SGLT1 was associated with survival in a cohort of patients with 
squamous cervical cancer treated with radiotherapy and cisplatin (107), thus having some 
similarities to our population. Those results suggested that patients expressing MAP17 and 
SGLT1 had better response to treatments that boost oxidative stress. In a more recent study, high 
MAP17 levels correlated with a poor prognosis and a higher grade of sarcoma. In this case, it was 
a heterogeneous group of different sarcoma histologies, most of them with metastatic disease. As 
patients were candidates for systemic therapies and not for radiotherapy, oxidative stress may not 
be implicated in this population (154).  Our analysis in laryngeal cancer showed that MAP17 
increased not only OS but also LRC and LDS in laryngeal cancer. On the other hand, SGLT-1 
expression was significantly related to MAP17. However, just a portion of tumour samples was 
positive (40%) and therefore survival could not be related to SGLT1 by itself. Nevertheless, the 
combination of high MAP17 and SGLT improved OS better than MAP17 alone.  
γH2AX phosphorylation has been studied as prognostic biomarker in early operable non-small 
cell lung cancer (NSCLC) and endometrial carcinomas. In the NSCLC study, low levels of 
pH2AX correlated with better survival outcomes. The combination of wild type p53 and low-
pH2AX phenotype showed also better survival. In the endometrial trial, pH2AX positively 
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correlated with p53 levels although the relation with survival could not be proved. However, 
patients in both studies were treated with surgery and not with radiotherapy (155, 156). Tumour cells 
from clinical specimens show constitutive activation of DNA damage signalling as demonstrated 
by the presence of gH2AX phosphorylation and other DDR signalling proteins (157,158, 159). This 
DDR activation was found to peak at early stage tumours, persisting further among malignant 
tumours mostly by inactivating p53 gatekeeper (159). It has been proposed that the DDR-network 
may serve as an inducible barrier to control the initial steps of tumour development by inducing 
p53-dependent senescence or apoptosis (157,158, 159). Further ongoing chronic DDR activation 
favours the outgrowth of malignant clones with genetic or epigenetic defects in DNA-repair 
mechanism such as those involved in the DDR pathway (159). Our samples, from already malignant 
tumours (stages II-IV), in which only a subset of them showed mutant p53, correlated with worse 
onset of the disease. It is likely DNA-damage defects inducing DDR activation have been carried 
through the malignant process and it is possible that other proteins are mutated in the process 
avoiding the requirement for p53 inactivation. 
pH2AH is a broad DNA damage marker that appears under different physiological conditions. 
Senescent cells display molecular characteristics of DNA damage (160,161,162). These markers 
include nuclear foci of phosphorylated histone H2AX, the localization at double-strand break 
sites of DNA-repair and DNA-damage checkpoint factors, such as 53BP1, MDC1 and NBS1 (163, 
164, 165). Senescent cells also contain activated forms of the DNA-damage checkpoint kinases Chk1 
and Chk2. During replicative senescence, markers of a DNA damage response localize at 
telomeres (164, 166), indicating that the DNA damage response is triggered by telomere shortening 
(167). Similarly, the redox potential also results in DNA damage and senescence (168). Very 
interestingly, oncogene-induced senescence has been found to induce DNA-damage due to an 
excess of replication forks. This oncogenic-induced hyper-replication signal, or replication stress, 
is associated with persistent DNA-damage (169, 170) inducing senescence (171). Therefore, not only 
senescence is viewed as a response to DNA-damage, but DNA-damage as a marker of senescence. 
In that sense, high pH2AX appeared in early stage tumors and is a marker of good prognosis 
(172,173). However, in our cohort, pH2AX levels are increased in advanced stages of tumors, and 
contrarily to this hypothesis, are a marker of bad prognosis, indicating that our pH2AX 
observations are not due to cellular senescence, neither by continuous proliferation nor by 
replication stress. 
In that line, phosphorylation of H2AX is not always a marker of DNA damage. It also can be a 
marker of activated mTOR, eliciting replicative stress and a pseudo DNA-damage in senescent 
cells (170, 174-177). The dynamics of senescence exhibit 2 different steps: cell cycle arrest and further 
acquisition of senescence features, which includes permanent arrest, termed geroconversion (170, 
178-180). If geroconversion is not activated, cells are only transiently arrested with the possibility of 
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resuming growth once the proliferation constraints have been eliminated (163, 180). It has also been 
shown that if mTOR is activated under conditions of proliferative arrest, then arrest becomes 
permanent and the cell undergoes senescence (178, 179, 181). Under these conditions of cell cycle 
arrest and mTOR activation, the phosphorylation of H2AX is launched, becoming a marker of 
cellular senescence (165, 171, 174, 181). In fact, rapamycin treatment, which inhibits mTOR, can divert 
senescence into quiescence, allowing the cell to resume growth once conditions are more 
favourable (182-185). Since mTOR is the master regulator of protein synthesis (186), it has been 
proposed that this contribution is due to the function of mTOR as a sensor of cellular nutrients 
and energy status as well as growth factor signals (187, 188). However, it has also been reported that 
mTOR activation in the context of growth arrest is perceived by the cells as an unwanted 
oncogenic signal, activating the replicative stress and pseudo DNA-damage signalling (165, 171, 174, 
181). In any case, high levels of pH2AX as marker of cellular senescence should be associated to 
better prognosis, and to some extent to early stage tumours. However, it will be of interest to 
correlate the levels of pH2AH with those of mTOR activation in laryngeal tumours to provide a 
more accurate hypothesis of the pH2AH inducers. 
Our data show that high levels of pH2AX correlate with better prognosis after treatment with 
DNA-damage agents such as cisplatin and radiotherapy, especially if cisplatin is given at optimal 
doses. These data are suggestive of a collaboration of DDR pathway activation, perhaps as an 
indicator of low DNA-repair ability and DNA-damaging agents in tumour therapy. The fact that 
doses of cisplatin are important for survival seems to confirm this hypothesis. In line with this, 
wt-P53 with high levels of pH2AX conforms a subgroup of good prognosis suggesting that P53 
activity is essential to drive physiological response to apoptosis (or senescence) of DNA-damage 
agents in tumours with DDR activated. 
These data are opposite to the found in early operable non-small cell lung cancer (NSCLC). In 
this study, low levels of pH2AX correlated with better survival outcomes. The combination of 
wild type p53 and low-phosphorylated ãH2AX phenotype showed also better survival. However, 
NSCLC patients were treated with surgery and not with radiotherapy (155). This lack of treatment 
with radiotherapy could be the cause of the different behaviour respect the pH2AX. Radiotherapy 
increases oxidative stress and reactive oxygen species that in combination with pre-existing DNA 
damage can increase cell damage above threshold inducing increased tumour efficacy. Our data 
support this hypothesis since combination with another ROS-inducing agent such as cisplatin is 
essential to gain better survival in these patients. Furthermore, the combination of MAP17 also 
supports the essential role of radiotherapy in this response. 
Therefore, this work suggests that high levels of MAP17 induced ROS that in turn increases 
DNA-damage and DDR signalling. Upon further DNA-damage and further increase in ROS 
molecules induced by cisplatin and RT treatment, tumours with higher oxidative stress (higher 
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MAP17, higher ROS denoted by higher pH2AX), are more suitable to undergo apoptosis in the 
presence of P53 activity. Our data seems to confirm that MAP17 and pH2AX are markers of 
structural DNA-damage in the laryngeal tumours that may become novel and valuable prognostic 
biomarkers for laryngeal carcinoma. Further prospective and controlled studies are needed in 
order to confirm these results and validate MAP17 and pH2AX as biomarkers for clinical use in 
larynx cancer.  
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• In our cohort, T4 primary tumour extension and patients who need a pre-treatment 
tracheotomy have worse LDS and do not to benefit of preservation treatments. Moreover, 
receiving an optimal platinum dose determined LDS. 
• Our analysis in laryngeal cancer showed a significant relationship between high MAP17 
protein expression and increased OS, suggesting that MAP17 expression is an 
independent biomarker for survival. 
• High MAP17 levels demonstrated better OS than low levels (67 months vs. 31.7 months, 
IC 95%; p<0.001). High MAP17 showed better LRC and LDS as well.  
• In addition, the associated high levels of MAP17 and SGLT showed improved OS, better 
than MAP17 alone.  
• Proof of concept experiments in vitro demonstrated that MAP17- expressing Hela cells 
are more sensitive to radiotherapy treatments in vitro. 
• Furthermore, antioxidant treatments reduced the sensitivity of MAP17- expressing Hela 
cells to a range similar to parental cells, confirming the relevance of the oxidative status 
of the tumours in the response to radiation.  
• pH2AX has a prognostic role in patients with laryngeal cancer. pH2AX was related to 
LDS (High- pH2AX HR 0.26, p = 0.02) in a cohort of 53 patients with larynx cancer.  
• When analysed together high-pH2AX expression and optimal dose of cisplatin received 
during radical treatment, there is a significant correlation with survival (72 vs 38.6 m, p= 
0.03) and LDS (66.9 vs 27 m, p = 0.019). 
• Also, patients with high-MAP17 and high-pH2AX showed to have better OS and LDS.  
• Our data suggest that inherent DDR pathway activation (measured by the end-point of 
phosphorylation of H2AX) is a valuable prognostic marker in patients with laryngeal 
carcinoma who received organ preservation approaches. 
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• En esta cohorte, los pacientes con afectación de tumor T4 y aquellos que requirieron 
traqueotomía previa al tratamiento obtuvieron peor SLF y no se beneficiaron de las 
terapias de preservación de órgano. Además, recibir una dosis de platino óptima 
determinaron la SLP. 
• En este estudio se demuestra la relación entre el aumento de la expresión proteica de 
MAP17 y el aumento de SG, sugiriendo que MAP17 es un biomarcador independiente 
de supervivencia.  
• Niveles altos de MAP17 se asocian a un aumento significativo de la SG en comparación 
con niveles bajos (67 m vs. 31.7 m, IC 95%; p<0.001). Alto-MAP17 también se 
correlaciona con CLR y SLF.  
• Además, el análisis conjunto de alto-MAP17 y SGLT aumentan la SG, mejor que el 
análisis independiente de MAP17. 
• La prueba de concepto demuestra que la expresión de MAP17 en células Hela confiere 
sensibilidad a la radioterapia in vitro.  
• De hecho, la adición de tratamientos antioxidantes redujeron la sensibilidad de la línea 
celular Hela con alta expresión de MAP17 hasta un rango similar a las células madre, 
confirmando la relevancia del estado oxidativo de los tumores para su respuesta a la 
radioterapia.  
• pH2AX es un factor pronóstico asociado a SLF (alto-pH2AX HR 0.26, p=0.02) en una 
cohorte de 53 pacientes con cáncer de laringe.  
•  El análisis conjunto de alto-pH2AX y dosis óptima de cisplatino recibido ha demostrado 
de forma significativa aumentar la SG (72 vs 38.6 m, p = 0.03) y la SLF (66.9 vs 27 m, 
p= 0.019). 
• Además, los pacientes con alto-MAP17 y alto-pH2AX obtuvieron mejor SG y SLF. 
• Los datos de este estudio sugieren que la activación inherente de los mecanismos de 
RDA, medido por la fosforilación de H2AX es un factor pronóstico en pacientes con 
cáncer de laringe que han recibido terapias de preservación de órgano.  
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